TWI652078B - Blood purification column - Google Patents

Blood purification column Download PDF

Info

Publication number
TWI652078B
TWI652078B TW103104538A TW103104538A TWI652078B TW I652078 B TWI652078 B TW I652078B TW 103104538 A TW103104538 A TW 103104538A TW 103104538 A TW103104538 A TW 103104538A TW I652078 B TWI652078 B TW I652078B
Authority
TW
Taiwan
Prior art keywords
blood
filter
adsorbent
column
mesh
Prior art date
Application number
TW103104538A
Other languages
Chinese (zh)
Other versions
TW201446289A (en
Inventor
藤枝洋曉
上野良之
田中和實
Original Assignee
東麗股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東麗股份有限公司 filed Critical 東麗股份有限公司
Publication of TW201446289A publication Critical patent/TW201446289A/en
Application granted granted Critical
Publication of TWI652078B publication Critical patent/TWI652078B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3627Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3643Priming, rinsing before or after use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3643Priming, rinsing before or after use
    • A61M1/3644Mode of operation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3643Priming, rinsing before or after use
    • A61M1/3644Mode of operation
    • A61M1/3652Mode of operation using gas, e.g. air
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672Means preventing coagulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26Synthetic macromolecular compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26Synthetic macromolecular compounds
    • B01J20/261Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26Synthetic macromolecular compounds
    • B01J20/262Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28023Fibres or filaments
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/2805Sorbents inside a permeable or porous casing, e.g. inside a container, bag or membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/75General characteristics of the apparatus with filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/10Location thereof with respect to the patient's body
    • A61M60/104Extracorporeal pumps, i.e. the blood being pumped outside the patient's body
    • A61M60/109Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems
    • A61M60/113Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems in other functional devices, e.g. dialysers or heart-lung machines
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28016Particle form
    • B01J20/28019Spherical, ellipsoidal or cylindrical

Abstract

本發明之課題在於:藉由血液淨化管柱所內藏之過濾片,使混入管柱內之逸氣性飛躍性地提高,而防止由殘存於管柱內之空氣引起之血液活化、或由吸附體與血液之接觸面積減少引起之吸附性能降低。 The object of the present invention is to prevent the activation of blood caused by the air remaining in the pipe string, or to prevent the activation of blood caused by the air remaining in the pipe string, by using the filter sheet contained in the blood purification pipe string to greatly improve the outgassing property mixed into the pipe string. The decrease in the contact area between the adsorbent and the blood reduces the adsorption performance.

本發明之血液淨化管柱之特徵在於:具有吸附體、與兩端為開放端之套管,於上述套管之內部收容有吸附體,上述套管兩端之一端為血液流入側端部,另一端為血液流出端部,於上述套管之血液流入側端部及/或血液流出側端部配置有過濾片,且上述過濾片滿足以下之必要條件: The blood purification tube string of the present invention is characterized in that it has an adsorbent body and a sleeve with open ends at both ends. The adsorbent body is housed inside the sleeve, and one end of the two ends of the sleeve is a blood inflow side end. The other end is a blood outflow end, and a filter is arranged on the blood inflow end and / or the blood outflow end of the cannula, and the filter meets the following necessary conditions:

(1)其開口率為5%以上且80%以下 (1) The aperture ratio is 5% or more and 80% or less

(2)其網眼之當量直徑為1μm以上且5000μm以下 (2) The equivalent diameter of the mesh is 1 μm or more and 5000 μm or less

(3)其網眼之當量直徑相對於上述吸附體之空隙之平均圓當量直徑的比率為45%以上。 (3) The ratio of the equivalent diameter of the mesh to the average circular equivalent diameter of the voids of the adsorbent is 45% or more.

Description

血液淨化管柱 Blood purification column

本發明係關於一種血液淨化管柱,其係用於血液淨化等之管柱,且逸氣性優異而不易引起血液導入時之迴路內血液凝固等。 The present invention relates to a blood purification pipe string, which is a pipe string used for blood purification and the like, and has excellent gas-exhausting property and does not easily cause blood coagulation in a circuit when blood is introduced.

已知有稱為血漿清除(Apheresis)療法之治療法,其係將患者之血液暫時抽出至體外,藉由吸附、過濾等處理而將抽出之血液中之病因物質去除,將其後之血液送回至患者之體內。該血漿清除療法可利用於藥物中毒、食物中毒、家族性高膽固醇血症之治療、或潰瘍性結腸炎、克隆氏病(Crohn's disease)、類風濕性關節炎等自體免疫性疾病之治療等,可用於將被認為成為該等疾病之原因之藥物、毒素、膽固醇等物質、或白血球或血小板等炎症性細胞自患者之血液中去除。 A treatment method called Apheresis therapy is known, which temporarily extracts the patient's blood outside the body, removes the causative substances in the extracted blood by treatment such as adsorption, filtration, and sends the subsequent blood. Back into the patient. This plasma clearance therapy can be used for the treatment of autotoxic diseases such as drug poisoning, food poisoning, familial hypercholesterolemia, or ulcerative colitis, Crohn's disease, rheumatoid arthritis, etc. It can be used to remove drugs, toxins, cholesterol and other substances, or inflammatory cells such as white blood cells or platelets, which are considered to be the cause of these diseases, from the blood of patients.

作為該血漿清除療法,已知有使用初級膜使血漿自血液分離,進而使該血漿通過次級膜之雙重膜過濾血漿置換療法(DFPP:Double Filtration Plasmapheresis)、或者對患者之體液直接進行處理之直接血液灌流療法(DHP:Direct Hemo Perfusion)。DHP由於處理簡便,故近年來正迅速普及。作為用於DHP之管柱之使用形態,除單獨使用管柱之形態以外,亦有於對腎功能衰竭患者等進行之透析中,與人工腎臟串列連接而使用之形態,亦可有效率地吸附成為作為透析併發症之透析相關性類澱粉變性症之原因物質之β2-微球蛋白(β2-Microglobulin)等。 As the plasma clearance therapy, a primary membrane is used to separate plasma from the blood, and then the plasma is passed through a dual membrane double membrane filtration plasma exchange therapy (DFPP: Double Filtration Plasmapheresis), or a patient's body fluid is directly processed. Direct HemoPerfusion (DHP). DHP is rapidly gaining popularity in recent years because of its ease of handling. As the use form of the DHP column, in addition to the form of using the column alone, it can also be used in series with an artificial kidney in dialysis for renal failure patients and the like, and it can also be efficiently used. adsorption become beta] as a cause of dialysis complication of dialysis-related amyloid degeneration of the substance of 2 - microglobulin (β 2 -Microglobulin) and the like.

於上述DHP中,使血液通過於內部收容有吸附體之管柱,利用吸附體吸附、去除血液中之去除對象物質。該管柱通常具有中空筒狀之套管,並於長度方向之兩端配置有設有血液之流入口、流出口之集管頭蓋(header cap),且於該套管之內部收容有吸附體。可藉由在套管之血液流入之端部及流出之端部配置具有較多微細開口之過濾片而使吸附體保持在套管內。 In the DHP described above, blood is passed through a column in which an adsorbent is housed inside, and the adsorbent is used to adsorb and remove substances to be removed from the blood. The tubular column usually has a hollow cylindrical sleeve, and a header cap with a blood inlet and an outlet is arranged at both ends in the length direction, and an adsorbent is contained inside the sleeve. . The absorbent body can be held in the cannula by arranging a filter with more fine openings at the blood inflow end and the outflow end of the cannula.

且說,通常於血液淨化管柱藉由DHP等而用作醫療用器具之情形時,於使用前進行所謂起動注水操作(priming),即,將生理食鹽水等進行通液、填充。此時,若於管柱內或迴路內產生空氣且殘留於管柱內,則會妨礙生理食鹽水等之通液、填充,有吸附體與血液之接觸面積減少,而導致血液淨化管柱之吸附、去除性能降低之情況。又,於配置於管柱之端部之過濾片之逸氣性較差,即,具有於空氣暫時進入至管柱內時該空氣不易逃逸至管柱外的過濾片之情形時,因殘存於管柱內之空氣而使管柱內之血液活化,變得容易引起血液凝固。尤其是於管柱以如上所述之與人工腎臟直列連接之形態使用之情形時,就操作性之觀點而言,於治療前進行之管柱及人工腎臟之洗淨(起動注水)較佳為以管柱與人工腎臟直列連接之狀態進行,但於使用未填充水之乾燥狀態或濕潤狀態之人工腎臟作為人工腎臟之情形時,大量之空氣流入管柱內。因此,作為用於管柱之過濾片,要求逸氣性優異之同時,生物相容性亦優異,即於血液流通時不易引起迴路內血液凝固等之性質。此前,存在將篩網用於DHP所使用之管柱之端部固定的專利(專利文獻1、2)。然而,作為關於篩網之規定,僅記載有應使用可將吸附體保持於管柱內之設計者,關於藉由設計篩網而改善上述逸氣性之情況未作記載。又,亦有於使用包含中空纖維狀或實心纖維 狀之吸附體作為管柱內之吸附體的管柱之兩端具備篩網之發明(專利文獻3)。然而,於該發明中亦無關於逸氣之意見,相反地,以管柱內吸附體之穩定保持、或管柱內流動性之提高為目的,以網狀布捲入吸附體而進行製作,就逸氣性之觀點而言,此種沿管柱長軸方向平行配置呈開口之篩網之情況欠佳。 In addition, when a blood purification tube string is used as a medical device by DHP or the like, a so-called priming operation is generally performed before use, that is, physiological saline or the like is fluidized and filled. At this time, if air is generated in the pipe string or circuit and remains in the pipe string, it will hinder the permeation and filling of physiological saline, etc., and the contact area between the adsorbent and the blood will be reduced, resulting in the blood purification pipe string. Cases of reduced adsorption and removal performance. In addition, when the filter sheet arranged at the end of the pipe string is poor in gas evasion, that is, when air enters the pipe string temporarily, the air cannot easily escape to the filter chip outside the pipe string because it remains in the pipe. The air in the column activates the blood in the column, which easily causes blood clotting. Especially when the column is used in the form of in-line connection with the artificial kidney as described above, from the viewpoint of operability, it is preferable that the column and the artificial kidney are washed (priming water injection) before treatment. It is performed in a state where the pipe string and the artificial kidney are connected in series. However, when an artificial kidney in a dry state or a wet state which is not filled with water is used as the artificial kidney, a large amount of air flows into the pipe string. Therefore, as a filter sheet for a column, it is required to be excellent in gas-exhausting property and excellent in biocompatibility, that is, it is difficult to cause blood coagulation and the like in the circuit when blood circulates. Previously, there were patents in which a screen is used for fixing the end of a pipe string used for DHP (Patent Documents 1 and 2). However, as a rule regarding the screen, only a designer who should use an adsorbent to hold the inside of the pipe string is described, and there is no description of the case where the above-mentioned outgassing property is improved by designing the screen. In addition, it is also used to contain hollow fiber or solid fibers. An invention in which the adsorbent having the shape of a column as an adsorbent in the column is provided with a screen at both ends (Patent Document 3). However, there is no opinion on the outgassing in the invention. On the contrary, for the purpose of stably maintaining the adsorption body in the column or improving the fluidity in the column, the mesh-like cloth is rolled into the adsorption body to make it. From the viewpoint of gas evasion, it is not good to arrange such screens with openings in parallel along the long axis direction of the column.

[先前技術文獻] [Prior technical literature] [非專利文獻] [Non-patent literature]

非專利文獻1:「化學工學與人工器官 第2版」,共立出版,1997年,p162~163 Non-Patent Document 1: "Chemical Engineering and Artificial Organs 2nd Edition", published by Kyoritsu, 1997, p162 ~ 163

[專利文獻] [Patent Literature]

專利文獻1:日本專利特開昭59-95051號公報 Patent Document 1: Japanese Patent Laid-Open No. 59-95051

專利文獻2:日本專利特開2009-254695號公報 Patent Document 2: Japanese Patent Laid-Open No. 2009-254695

專利文獻3:日本專利特開2010-148851號公報 Patent Document 3: Japanese Patent Laid-Open No. 2010-148851

本發明之目的在於:藉由血液淨化管柱所內藏之過濾片,使混入管柱內之逸氣性飛躍性地提高,而防止由殘存於管柱內之空氣引起之血液活化、或由吸附體與血液之接觸面積減少引起之吸附性能降低。 The purpose of the present invention is to prevent the activation of blood caused by the air remaining in the column, or to prevent the activation of blood caused by the air remaining in the column, by using the filter sheet contained in the blood purification tube string to greatly improve the outgassing property. The decrease in the contact area between the adsorbent and the blood reduces the adsorption performance.

本發明之血液淨化管柱係如下者:具有吸附體、與兩端為開放端之套管,於套管之內部收容有吸附體,套管兩端之一端為血 液流入側端部,另一端為血液流出側端部,於該血液流入端部及/或血液流出側端部配置有過濾片,且過濾片滿足以下之必要條件。 The blood purification tube column of the present invention is as follows: a sleeve having an adsorbent body and two ends with open ends, the adsorbent body is housed inside the sleeve, and one end of the sleeve is blood The other end is the end of the liquid inflow side, and the other end is the end of the blood outflow side. A filter is arranged at the end of the blood inflow and / or the end of the blood outflow side, and the filter meets the following requirements.

(1)開口率為5%以上且80%以下 (1) Opening ratio is 5% or more and 80% or less

(2)網眼之當量直徑為1μm以上且5000μm以下 (2) The equivalent diameter of the mesh is 1 μm or more and 5000 μm or less

(3)網眼之當量直徑相對於上述吸附體之空隙之平均圓當量直徑的比率為45%以上 (3) The ratio of the equivalent diameter of the mesh to the average circular equivalent diameter of the voids of the adsorbent is 45% or more

關於上述(3),所收容之吸附體係內部具有空隙者,但於本發明中,發現如下情況,即上述過濾片網眼之當量直徑與上述吸附體之空隙之平均圓當量直徑密切相關,且藉由使兩者之比率適當化,從而使逸氣性提高。 Regarding the above (3), there are voids in the contained adsorption system, but in the present invention, it is found that the equivalent diameter of the mesh of the filter sheet is closely related to the average equivalent diameter of the voids of the adsorbent, and By optimizing the ratio between the two, the outgassing property is improved.

又,作為過濾片,其親疏水性重要,即,其材質之接觸角處於適當範圍者較佳。因此,作為過濾片之材質,較佳為包含選自聚烯烴系樹脂、聚醯胺系樹脂、氟系樹脂中之至少1種素材,更佳為包含選自聚丙烯、聚乙烯、尼龍6、尼龍66及該等之衍生物中之至少1種素材,進而較佳為包含聚丙烯或其衍生物中之至少任一種之素材者。 In addition, as a filter, its hydrophilicity is important, that is, a material having a contact angle within a suitable range is preferred. Therefore, as the material of the filter sheet, it is preferable to include at least one material selected from the group consisting of polyolefin resin, polyamide resin, and fluorine resin, and it is more preferable to include a material selected from polypropylene, polyethylene, nylon 6, Nylon 66 and its derivatives are at least one kind of material, and more preferably one containing polypropylene or its derivative.

根據本發明,可提供一種可將於使用前進行之起動注水操作時等產生之空氣高效率地去除至管柱外,從而血液流通時之迴路內血液凝固不易產生的血液淨化管柱。 According to the present invention, it is possible to provide a blood purification tube string which can efficiently remove air generated during a water injection operation or the like performed before use to the outside of the tube string, so that blood coagulation in the circuit during blood circulation is difficult to occur.

1‧‧‧集管頭蓋 1‧‧‧ header cap

2‧‧‧被處理液流出口 2‧‧‧ Outlet of treated liquid

3‧‧‧被處理液流入口 3‧‧‧ liquid inlet

4‧‧‧出口側過濾片 4‧‧‧ exit side filter

5‧‧‧入口側過濾片 5‧‧‧Inlet side filter

6‧‧‧套管 6‧‧‧ casing

7‧‧‧吸附體 7‧‧‧ adsorbent

8‧‧‧血液淨化管柱 8‧‧‧ blood purification tube

9‧‧‧空氣注入用注射器 9‧‧‧Air injection syringe

10‧‧‧泵 10‧‧‧ Pump

11‧‧‧燒杯 11‧‧‧ beaker

12‧‧‧純水 12‧‧‧ pure water

13‧‧‧單側安裝篩網之管柱 13‧‧‧Single-sided installation screen

14‧‧‧熱水浴(37℃) 14‧‧‧ hot bath (37 ℃)

15‧‧‧廢棄用燒杯 15‧‧‧ Disposable beakers

16‧‧‧循環用血漿 16‧‧‧Circulation plasma

17‧‧‧清除率測定用血漿 17‧‧‧Plasma for measuring clearance

圖1係關於內藏有吸附體之管柱之圖。 Figure 1 is a diagram of a column with an adsorbent embedded therein.

圖2係關於單側安裝篩網之管柱之圖。 Figure 2 is a diagram of a pipe string with a screen installed on one side.

圖3係關於內藏有吸附體之管柱內之空氣去除率測定之迴路圖。 Fig. 3 is a circuit diagram for measuring the air removal rate in a pipe string having an adsorbent therein.

圖4係關於單側安裝篩網之管柱內之空氣去除率測定之迴路圖。 Fig. 4 is a circuit diagram for measuring the air removal rate in a pipe string with a screen installed on one side.

圖5係關於血液淨化管柱之β2-MG清除率測定之迴路圖。 Fig. 5 is a circuit diagram for measuring β 2 -MG clearance of a blood purification tube string.

本發明之血液淨化管柱係具有填充於管柱內之吸附體、及用以保持吸附體之過濾片者,且將該過濾片之開口率設為5%以上且80%以下。 The blood purification pipe string of the present invention includes an adsorbent filled in the pipe string and a filter for holding the adsorbent, and the opening ratio of the filter is 5% or more and 80% or less.

此處,關於過濾片之開口率之測定方法,係利用光學顯微鏡,自於將過濾片配置於管柱內時血流流經過濾片之方向,即,與於管柱兩端有血液流入口及流出口之情形時從入口向出口之方向相同之方向進行觀察,任意觀察5mm見方所包圍之範圍,若將該範圍所含有之構成過濾片之構造體所占之面積設為A mm2,則開口率可以下述式進行表示。 Here, the method of measuring the aperture ratio of the filter is based on the direction of blood flow through the filter when the filter is placed in the column using an optical microscope, that is, there are blood inlets at both ends of the column Observe the same direction from the inlet to the outlet in the case of the outflow. Observe the range surrounded by 5mm square arbitrarily. If the area occupied by the structure constituting the filter in this range is set to A mm 2 , The aperture ratio can be expressed by the following formula.

開口率(%)=(25-A)/25×100 Opening rate (%) = (25-A) / 25 × 100

針對成為對象之1片過濾片,選擇任意5處之5mm見方範圍而測定開口率,並求出其平均值。再者,算出之開口率係將小數點以後第1位進行四捨五入。 Regarding one of the target filters, a 5 mm square range was selected at arbitrary five places to measure the aperture ratio, and the average value was obtained. The calculated aperture ratio is rounded off to the first decimal place.

若開口率過高,則過濾片之強度不足,而變得難以將吸附體穩定地保持於套管。另一方面,若開口率過低,則流動之阻力增加,逸氣性惡化。又,變得容易引起管柱內血液通過時之壓力損失之增大、或於過濾片形成有血栓等時管柱壓之上升。根據上述情況,作為開口率之上限,為80%以下,較佳為70%以下,更佳為成為66%以下。另一方面,作為下限,為5%以上,較佳為16%以上,更佳為成為21%以上。 When the aperture ratio is too high, the strength of the filter is insufficient, and it becomes difficult to stably hold the adsorbent body in the sleeve. On the other hand, if the aperture ratio is too low, the resistance to flow increases, and the outgassing property deteriorates. In addition, it becomes easy to cause an increase in pressure loss when blood in the column passes, or an increase in the column pressure when a clot is formed in the filter. According to the above, the upper limit of the aperture ratio is 80% or less, preferably 70% or less, and more preferably 66% or less. On the other hand, the lower limit is 5% or more, preferably 16% or more, and more preferably 21% or more.

又,上述過濾片之網眼之當量直徑係重要之因子。網眼之當量直徑之測定方法係如下所述。即,於過濾片之網眼於厚度方向均勻之情形時,利用光學顯微鏡自過濾片之厚度方向對過濾片進行觀察,於過濾片之網眼於厚度方向不均勻之情形時,利用切割器等將網眼成為最小之厚度部分切片,同樣地利用光學顯微鏡自上述垂直方向進行觀察,任意抽選30點過濾片之空隙部,測定各自之面積S,並藉由下述式算出各自之網眼之當量直徑。其後,算出30點之測定值之平均值,並將小數點以後第1位進行四捨五入。 The equivalent diameter of the mesh of the filter is an important factor. The measuring method of the equivalent diameter of a mesh is as follows. That is, when the mesh of the filter is uniform in the thickness direction, use an optical microscope to observe the filter from the thickness direction of the filter, and when the mesh of the filter is not uniform in the thickness direction, use a cutter, etc. The mesh was cut to a minimum thickness, and similarly observed from the vertical direction with an optical microscope. 30 voids of the filter were arbitrarily selected, and the respective areas S were measured. The meshes of the respective meshes were calculated by the following formula. Equivalent diameter. Thereafter, an average value of the measured values at 30 points was calculated, and the first digit after the decimal point was rounded.

網眼之當量直徑=2×(S/π)1/2 Equivalent diameter of mesh = 2 × (S / π) 1/2

若網眼之當量直徑過大,則變得難以於管柱內保持吸附體。又,倘若於迴路或管柱內產生異物時,無法利用過濾片捕捉之可能性亦提高。因此,具體而言,網眼之當量直徑較佳為設為自縱方向觀察管柱時之各吸附體每1個之截面面積的10倍以下,更佳為5倍以下,進而較佳為2.8倍以下。此處所謂各吸附體每1個之截面面積,例如若為實心纖維,則係每根纖維之橫截面之截面面積,若為球狀之珠粒,則係每個珠粒之以通過珠粒中心部之直線切斷時獲得之面的面積。另一方面,若過濾片之網眼之當量直徑過小,則流動之阻力增加,逸氣性變差。又,變得容易引起管柱內血液通過時之壓力損失之增大、或於過濾片形成有血栓等時管柱壓之上升。根據上述情況,作為網眼之當量直徑之上限,為5000μm以下,較佳為800μm以下,更佳為成為400μm以下。作為網眼之當量直徑之下限,為1μm以上,較佳為5μm以上,更佳為成為10μm以上。 If the equivalent diameter of the mesh is too large, it becomes difficult to hold the adsorbent in the column. In addition, if foreign matter is generated in a circuit or a pipe string, the possibility that the filter cannot be used for capturing is also increased. Therefore, specifically, the equivalent diameter of the mesh is preferably 10 times or less, more preferably 5 times or less, and even more preferably 2.8 times the cross-sectional area of each adsorbent when the column is viewed from the longitudinal direction. Times below. Here, the cross-sectional area of each adsorbent is, for example, if it is a solid fiber, the cross-sectional area of each fiber cross-section. If it is a spherical bead, it means that each bead passes through the bead. The area of the surface obtained when the straight line at the center is cut. On the other hand, if the equivalent diameter of the mesh of the filter is too small, the resistance to flow increases and the outgassing property becomes poor. In addition, it becomes easy to cause an increase in pressure loss when blood in the column passes, or an increase in the column pressure when a clot is formed in the filter. According to the above, the upper limit of the equivalent diameter of the mesh is 5,000 μm or less, preferably 800 μm or less, and more preferably 400 μm or less. The lower limit of the equivalent diameter of the mesh is 1 μm or more, preferably 5 μm or more, and more preferably 10 μm or more.

又,逸氣性可以如下所示之方法進行評價。於血液淨化管柱之兩端配置過濾片及具備被處理液之流入口及流出口之集管頭 蓋,其次利用純水將管柱內部洗淨後,利用蓋將各端口密封。將該管柱以其長度方向垂直於地面之方式安裝於如圖2之逸氣性試驗用迴路中,以下述程序測定5次被篩網截留之管柱內空氣之去除率,並藉由將小數點以後第1位進行四捨五入而求出該空氣去除率之平均值。 The outgassing property can be evaluated by the following method. Filter plates and collecting headers with the inlet and outlet of the liquid to be treated are arranged at both ends of the blood purification tube string After the inside of the column was washed with pure water, the ports were sealed with the cover. This pipe string was installed in the circuit for the gas escape test as shown in Fig. 2 with its length direction perpendicular to the ground. The removal rate of air in the pipe string trapped by the screen was measured 5 times by the following procedure, and The first digit after the decimal point is rounded to find the average value of the air removal rate.

(1)使用泵,使純水以流速100ml/s進行循環直至迴路內之空氣完全逃逸。根據需要對管柱進行敲打等而將空氣完全逐出。 (1) Use a pump to circulate pure water at a flow rate of 100 ml / s until the air in the circuit completely escapes. If necessary, tap the pipe string to completely expel the air.

(2)停止泵,一面注意不要使空氣混入一面將管柱自迴路取下,分別於被處理液之流入口及流出口蓋上蓋。測定此時之管柱重量,設為A。 (2) Stop the pump, while taking care not to mix air, remove the pipe string from the circuit, and cover the inlet and outlet of the liquid to be treated respectively. The column weight at this time was measured and set to A.

(3)將重量測定後之管柱再次裝回迴路中,使純水以流速100ml/s進行循環。 (3) The column after the weight measurement is put back into the circuit again, and the pure water is circulated at a flow rate of 100 ml / s.

(4)從自管柱之被處理液流入口至迴路之上游部1cm處,使用注射器歷時5秒鐘注入10ml之乾燥空氣。 (4) From the inlet of the liquid to be treated of the column to the upstream of the circuit 1 cm, use a syringe to inject 10 ml of dry air for 5 seconds.

(5)直接以流速100ml/s使純水循環1分鐘。該期間,迴路為靜置之狀態。 (5) Circulate pure water directly at a flow rate of 100 ml / s for 1 minute. During this period, the circuit is in a static state.

(6)停止泵,一面注意不要使空氣混入一面將管柱自迴路取下,分別於被處理液之流入口及流出口蓋上蓋。測定此時之管柱重量,設為B。 (6) Stop the pump, while taking care not to mix air, remove the pipe string from the circuit, and cover the inlet and outlet of the liquid to be treated respectively. The column weight at this time was measured, and it was set to B.

(7)根據下述式算出管柱內空氣之去除率。 (7) Calculate the removal rate of air in the column according to the following formula.

管柱內空氣去除率(%)=(A-B)/A×100。再者,此處所謂空氣去除率較佳為43%以上,更佳為55%以上,進而較佳為63%以上。 Air removal rate in the column (%) = (A-B) / A × 100. The air removal rate is preferably 43% or more, more preferably 55% or more, and even more preferably 63% or more.

本發明中所謂吸附體,係與上述醫療設備中之吸附體相同,為吸附、去除血液中之去除對象物質者。作為供填充之吸附體之形態,可為平膜狀、粉狀、球狀粒子、破碎粒子、塊狀連續體、纖維狀、管狀、中空纖維狀、實心纖維狀、粒狀、板狀、破碎中空纖維狀、 破碎實心纖維狀等中之任一形狀。其中,若為沿管柱長度方向平行配置之直線形狀之管狀、中空纖維狀、實心纖維狀,則流路亦成為直線形狀,又,流路長度可設為最小,因此空氣不易被截留,故而較佳。進而,於中空纖維狀或實心纖維狀之情形時,可藉由分別使膜厚部或纖維內部之形態為適合吸附之多孔質而充分確保吸附面積,從而可有效率地將血液中所含有之吸附目標物質吸附去除,又,與極細纖維或破碎中空纖維、破碎實心纖維等相比,有即便於患者之全血等被處理液之黏性較高,而於管柱內凝固等之風險較高之情形時亦可使用之優點。又,尤佳為實心纖維狀。其原因在於:於中空纖維之情形時,有於中空纖維之內側與外側壓力損失不同之情形等時,被處理液之流量於中空纖維內外產生差異,結果引起管柱之吸附效率降低之擔憂。又,為了使中空纖維之內側與外側之壓力損失同等,而中空纖維之內徑及管柱填充率產生較大制約。進而,於填充有中空纖維之管柱流過血液之情形時,與管柱內之中空纖維外部之環境相比,中空纖維之中空部係被固定之封閉環境,而有容易形成血栓等之擔憂。再者,中空纖維外部之間隙由於纖維於管柱內活動而變形,因此並非為固定之封閉環境。此處所謂上述沿管柱長度方向平行配置之直線形狀,係指1根纖維之兩側端面以儘可能接近最短距離之長度接觸於管柱之入口、出口端面的形狀。其中,纖維亦可產生捲曲等捲縮。又,多孔質之吸附體較佳為其多孔質構造於厚度方向為均質。藉此,可使有助於吸附之面積增大。另一方面,於孔構造為梯度之非對稱構造或於厚度方向具有不規則構造之情形時,吸附體之比表面積降低,故而欠佳。 The so-called adsorbent in the present invention is the same as the adsorbent in the above-mentioned medical equipment, and is a substance that adsorbs and removes a substance to be removed from the blood. The form of the adsorbent to be filled can be flat film, powder, spherical particles, broken particles, massive continuous bodies, fibrous, tubular, hollow fiber, solid fiber, granular, plate, broken Hollow fibrous, Any shape such as a broken solid fibrous shape. Among them, if it is a linear, tubular, hollow fiber, or solid fiber shape arranged in parallel along the length of the column, the flow path will also be a straight line. The length of the flow path can be set to a minimum, so air is not easily trapped, so Better. Furthermore, in the case of hollow fibrous or solid fibrous, the adsorption area can be sufficiently ensured by making the thickness of the membrane or the inside of the fiber porous, which is suitable for adsorption, so that the content contained in blood can be efficiently contained. The target substance is adsorbed and removed. Compared with ultrafine fibers, broken hollow fibers, broken solid fibers, etc., there is a higher viscosity of the treated liquid, such as the patient's whole blood, and a higher risk of coagulation in the column. The advantage can also be used in high situations. Further, it is particularly preferable that the fibers are solid and fibrous. The reason is that in the case of hollow fibers, there are cases where the pressure loss between the inside and outside of the hollow fiber is different, etc., the flow rate of the liquid to be treated varies between the inside and outside of the hollow fiber, and as a result, the adsorption efficiency of the column may be reduced. In addition, in order to make the pressure loss on the inside and the outside of the hollow fiber equal, the inner diameter of the hollow fiber and the filling rate of the pipe string are greatly restricted. Furthermore, when a tubular string filled with hollow fibers flows through the blood, compared with the environment outside the hollow fibers in the tubular string, the hollow portions of the hollow fibers are fixed in a closed environment, and there is a concern that blood clots are likely to be formed. . Furthermore, the gaps outside the hollow fibers are deformed due to the movement of the fibers in the pipe string, so they are not a fixed closed environment. Here, the above-mentioned linear shape arranged in parallel along the length of the pipe string refers to a shape in which the end faces on both sides of a fiber contact the inlet and outlet end faces of the pipe string as close as possible to the shortest distance. Among them, the fibers may be crimped, such as crimps. Moreover, it is preferable that the porous adsorbent has a porous structure that is homogeneous in the thickness direction. Thereby, the area contributing to adsorption can be increased. On the other hand, when the pore structure is an asymmetric structure with a gradient or an irregular structure in the thickness direction, the specific surface area of the adsorbent decreases, which is unfavorable.

於纖維產生捲曲等捲縮之情形時,為了求出下述之填充率,而以將纖維兩端拉長之直線形狀之狀態測定纖維長度,作為管柱 內所內藏之直線形狀之纖維之長度方向長度的測定方法,係將自管柱抽出之纖維之一端用膠帶固定,對另一端賦予3g左右之配重,迅速測定纖維成為直線狀時之全長。關於該測定,係針對管柱內之纖維中任意30根進行,並算出30根之平均值。 When the fiber is crimped, such as crimping, in order to obtain the filling rate described below, the fiber length is measured in a state of a linear shape where both ends of the fiber are elongated, and it is used as a pipe string. The measuring method of the length of the linear fiber contained in the length direction is to fix one end of the fiber extracted from the column with tape, and give a weight of about 3g to the other end to quickly measure the total length of the fiber when it becomes linear. . This measurement was performed on arbitrary 30 fibers in the column, and the average value of 30 fibers was calculated.

又,於本發明中,過濾片網眼之當量直徑相對於吸附體之空隙之平均圓當量直徑的比率為45%以上,較佳為50%以上,進而較佳為56%以上。上述比率較佳為400%以下,更佳為280%以下,進而較佳為220%以下。此處所謂上述平均圓當量直徑De,係如非專利文獻1所記載般,於吸附體為如管狀、中空纖維狀、實心纖維狀等般沿管柱長度方向平行配置之直線形狀之情形時,由下述式表示。 In the present invention, the ratio of the equivalent diameter of the mesh of the filter to the average circular equivalent diameter of the voids of the adsorbent is 45% or more, preferably 50% or more, and more preferably 56% or more. The above ratio is preferably 400% or less, more preferably 280% or less, and still more preferably 220% or less. Here, the above-mentioned average circular equivalent diameter De is as described in Non-Patent Document 1 when the adsorbent has a linear shape arranged parallel to the length of the column such as a tube, a hollow fiber, or a solid fiber, etc. It is represented by the following formula.

吸附體空隙之平均圓當量直徑De=4×Af/Wp Average circular equivalent diameter of the gap of the adsorbent De = 4 × Af / Wp

式中之Af係流路截面面積,且係自與套管之長度方向垂直之方向之截面的截面面積減去吸附體所占之同方向之截面之截面面積的總和而獲得之值。該吸附體所占之截面面積之總和可由利用下述纖維直徑之測定方法而獲得之纖維直徑D0與管柱內填充纖維根數N,以下述式求出。 Af in the formula is the cross-sectional area of the flow path, and is a value obtained by subtracting the sum of the cross-sectional area of the cross-section in the direction perpendicular to the length direction of the sleeve and the cross-sectional area of the cross-section in the same direction occupied by the adsorbent. The total of the cross-sectional area occupied by this adsorbent can be determined from the fiber diameter D0 obtained by the following fiber diameter measurement method and the number N of filled fibers in the column, and can be determined by the following formula.

吸附體所占之截面面積之總和=(D0/2)2×π×N Sum of the cross-sectional area occupied by the adsorbent = (D0 / 2) 2 × π × N

又,Wp係濕潤邊長,且係套管之內側表面積與吸附體之總表面積之和。吸附體之總表面積可由纖維直徑D0與管柱內填充纖維根數N及纖維之長度方向長度L,以下述式求出。 Wp is the length of the wet side, and is the sum of the inner surface area of the sleeve and the total surface area of the adsorbent. The total surface area of the adsorbent can be determined by the following formula from the fiber diameter D0, the number N of the filled fibers in the column, and the length L of the fibers in the length direction.

吸附體之總表面積=D0×π×L Total surface area of the adsorbent = D0 × π × L

套管之形狀係兩端為開放端,例如可舉出四角筒體、六角筒體等角筒體或圓筒體,其中,較佳為圓筒體,尤其是截面為正圓狀之筒體。其原因在於:藉由使套管不具有角,而可抑制血液於角部滯留。又, 藉由將兩側設為開放端,可使血液之流動不易成為紊流而將壓力損失控制在最小限度。又,套管較佳為包含塑膠或金屬等之器具。於塑膠之情形時,例如可使用機械強度、熱穩定性優異之熱塑性樹脂。作為此種熱塑性樹脂之具體例,可舉出:聚碳酸酯系樹脂、聚乙烯醇系樹脂、纖維素系樹脂、聚酯系樹脂、聚芳酯系樹脂、聚醯亞胺系樹脂、環狀聚烯烴系樹脂、聚碸系樹脂、聚醚碸系樹脂、聚烯烴系樹脂、聚苯乙烯樹脂、聚乙烯醇系樹脂、及該等之混合物。該等中,就套管所要求之成形性、透明性、放射線耐性之方面而言,較佳為聚苯乙烯、聚碳酸酯及該等之衍生物。其原因在於:透明性優異之樹脂由於可於血液灌流時確認內部之情況,故方便確保安全性,放射線耐性優異之樹脂對在滅菌時進行放射性照射之情形較佳。於前者之情形時,藉由利用模具之射出成形、或對素材進行切削加工而製作器具,於後者之情形時,藉由對素材進行切削加工而製作器具。其中,就成本或成形性、重量、血液相容性之觀點而言,可較佳地使用塑膠。 The shape of the sleeve is an open end at both ends. For example, a rectangular cylinder or a cylindrical cylinder such as a quadrangular cylinder or a hexagonal cylinder can be mentioned. Among them, a cylindrical body is preferred, and a cylindrical body having a perfect circular cross section is particularly preferred. . The reason is that blood can be prevented from staying in the corner by making the cannula no corner. also, By setting the two sides as open ends, blood flow is less likely to become turbulent and pressure loss is minimized. The sleeve is preferably a device including plastic or metal. In the case of plastic, for example, a thermoplastic resin having excellent mechanical strength and thermal stability can be used. Specific examples of such thermoplastic resins include polycarbonate resins, polyvinyl alcohol resins, cellulose resins, polyester resins, polyarylate resins, polyimide resins, and cyclic resins. Polyolefin resin, polyfluorene resin, polyether resin, polyolefin resin, polystyrene resin, polyvinyl alcohol resin, and mixtures thereof. Among these, in terms of formability, transparency, and radiation resistance required for the sleeve, polystyrene, polycarbonate, and derivatives thereof are preferred. This is because a resin with excellent transparency can confirm the internal condition during blood perfusion, so it is convenient to ensure safety, and a resin with excellent radiation resistance is better for radioactive irradiation during sterilization. In the former case, an appliance is produced by injection molding using a mold or by cutting the material, and in the latter case, an appliance is produced by cutting the material. Among these, plastic is preferably used from the viewpoints of cost, formability, weight, and blood compatibility.

又,於吸附體為如粒子狀、粉狀、破碎線狀等般相對於管柱內血液流動方向並非為直線形狀之形態之情形時,平均圓當量直徑De可以下述式求出。 When the adsorbent is in a shape that is not linear with respect to the direction of blood flow in the column such as particles, powder, or broken lines, the average circular equivalent diameter De can be determined by the following formula.

吸附體空隙之平均圓當量直徑De=(32×μ×L×u/△P)1/2 Average circular equivalent diameter of the gap of the adsorbent De = (32 × μ × L × u / △ P) 1/2

式中之μ係被處理液之黏度,L係吸附體填充部之長度方向之長度,u係管柱內平均流速,△P係自管柱入口部之壓力損失減去管柱出口部之壓力損失而獲得之值。 In the formula, μ is the viscosity of the liquid to be treated, L is the length in the length of the adsorbent filling part, u is the average flow velocity in the column, and △ P is the pressure loss from the inlet of the column minus the pressure at the outlet of the column. The value gained through loss.

於過濾片網眼之當量直徑相對於吸附體之空隙之平均圓當量直徑的比率未滿45%之情形時,相對於通過管柱內之空氣之截面面積,過濾片之網眼明顯較小,因此有難以通過過濾片而空氣容易 滯留於管柱內之傾向。另一方面,於過濾片網眼之當量直徑相對於吸附體之空隙之平均圓當量直徑的比率大於400%之情形時,有吸附體變得容易自過濾片網眼流出,而不易保持於管柱內之吸附體之情形。再者,算出之網眼之當量直徑係將小數點以後第1位進行四捨五入而求出,之後算出上述比率。 In the case where the ratio of the equivalent diameter of the mesh of the filter to the average circular equivalent diameter of the voids of the adsorbent is less than 45%, the mesh of the filter is significantly smaller than the cross-sectional area of the air passing through the column. Therefore, it is difficult to pass the filter and the air is easy The tendency to stay in the column. On the other hand, when the ratio of the equivalent diameter of the mesh of the filter to the average circular equivalent diameter of the voids of the adsorbent is more than 400%, the adsorbent becomes easy to flow out of the filter mesh, and it is difficult to keep it in the tube. The condition of the adsorbent in the column. The calculated equivalent diameter of the mesh is obtained by rounding off the first digit after the decimal point, and then calculating the above ratio.

又,於填充中空纖維或實心纖維作為吸附體之情形時,若其纖維直徑(中空纖維之情形時為纖維外徑)過小,則有使管柱之壓力損失增大,或纖維本身穿過過濾片之危險性。另一方面,於過大之情形時,吸附體與血液之接觸面積降低,而使血液淨化之效率惡化。因此,纖維直徑較佳為1000μm以下,更佳為450μm以下,進而較佳為280μm以下,作為下限,較佳為5μm以上,更佳為30μm以上,進而較佳為70μm以上。 In addition, when the hollow fiber or solid fiber is filled as an adsorbent, if the fiber diameter (the outer diameter of the fiber in the case of a hollow fiber) is too small, the pressure loss of the pipe string increases, or the fiber itself passes through. Dangers of filters. On the other hand, when it is too large, the contact area between the adsorbent and blood is reduced, and the efficiency of blood purification is deteriorated. Therefore, the fiber diameter is preferably 1,000 μm or less, more preferably 450 μm or less, and even more preferably 280 μm or less. As a lower limit, 5 μm or more, more preferably 30 μm or more, and even more preferably 70 μm or more.

關於纖維直徑之測定方法,係於填充於管柱內之纖維中任意抽選50根,將該等纖維洗淨後,利用純水進行完全置換,夾入載玻片與蓋玻片之間,使用投影機(例如Nikon公司製造之V-10A),針對同一根纖維,任意測定2處各自之纖維之外徑(最外周之直徑),採用其平均值,並將小數點以後第1位進行四捨五入。再者,於所填充之中空纖維根數未滿50根之情形時,對全部纖維進行測定,且同樣地採用平均值。 As for the measurement method of the fiber diameter, 50 fibers are randomly selected from the fibers filled in the column, and after washing these fibers, they are completely replaced with pure water, sandwiched between a slide glass and a cover glass, and used. For a projector (such as the V-10A manufactured by Nikon), the outer diameter (outer diameter) of each of the two fibers is arbitrarily measured for the same fiber, the average value is used, and the first digit after the decimal point is rounded. . When the number of filled hollow fibers is less than 50, all fibers are measured, and the average value is similarly used.

又,就防止吸附體隨著血流流出之觀點而言,作為過濾片之網眼,較佳為設定為血液通過但吸附體不通過之程度。即,網眼較佳為設為填充之每個吸附體之直徑以下。 From the viewpoint of preventing the adsorbent from flowing out of the bloodstream, the mesh of the filter is preferably set to such an extent that blood passes through but the adsorbent does not pass. That is, the mesh is preferably set to a diameter of each of the adsorbed bodies to be filled.

作為過濾片之素材,可單獨或組合使用鋁等金屬材料、絹等天然材料、及高分子化合物等。其中,就成本或強度、重量、生 物相容性等觀點而言,可較佳地使用高分子化合物,尤佳為包含選自聚烯烴系樹脂、聚醯胺系樹脂、氟系樹脂中之至少1種素材。其理由可舉出:對血液淨化管柱之過濾片要求親疏水性之控制。即,若使用過濾片材料與水之接觸角較高之素材,則可使流入管柱內之逸氣性提高。關於過濾片與水之接觸角,若過低,則有逸氣性惡化而空氣殘存於管柱內之傾向。另一方面,於過高之情形時,引起蛋白質等向過濾片之非特異性吸附,其導致血小板之附著等,從而引起血液凝固等。因此,作為接觸角之上限,較佳為125°以下,更佳為108°以下,尤佳為104°以下,另一方面,作為下限,較佳為66°以上,更佳為72°以上,尤佳為82°以上。 As the material of the filter sheet, metal materials such as aluminum, natural materials such as silk, and polymer compounds can be used alone or in combination. Among them, in terms of cost or strength, weight, From the viewpoint of physical compatibility and the like, a polymer compound can be preferably used, and it is particularly preferable to include at least one material selected from a polyolefin resin, a polyamide resin, and a fluorine resin. The reason can be cited as: the control of the hydrophilicity and hydrophobicity is required for the filter of the blood purification column. That is, if a material having a high contact angle between the filter material and water is used, the outgassing ability flowing into the pipe string can be improved. If the contact angle between the filter and water is too low, the outgassing property is deteriorated and air tends to remain in the pipe string. On the other hand, when it is too high, non-specific adsorption of proteins and the like to the filter is caused, which leads to platelet adhesion and the like, thereby causing blood coagulation and the like. Therefore, the upper limit of the contact angle is preferably 125 ° or less, more preferably 108 ° or less, and even more preferably 104 ° or less. On the other hand, as the lower limit, it is preferably 66 ° or more, and more preferably 72 ° or more. Particularly preferred is 82 ° or more.

此處,過濾片之類之構造體之接觸角係受到纖維直徑、纖維密度影響,因此過濾片材料與水之接觸角係指製作包含與該過濾片相同素材之均勻之薄膜後,測定薄膜表面與液體表面之角度而獲得之液體的內側之角度。具體而言,製作使過濾片溶解於其良溶劑中而成之溶液,使該溶液流入鋁製盤中,於乾燥環境下使良溶劑蒸發並使之固化,藉此製作薄膜。 Here, the contact angle of a structure such as a filter is affected by the fiber diameter and fiber density. Therefore, the contact angle between the filter material and water refers to measuring the surface of the film after making a uniform film containing the same material as the filter. The angle of the inside of the liquid obtained from the angle to the surface of the liquid. Specifically, a solution is prepared by dissolving a filter in a good solvent, the solution is flowed into an aluminum pan, and the good solvent is evaporated and solidified in a dry environment to produce a thin film.

接觸角之測定可使用接觸角計(例如,協和界面科學公司製造,DropMaster DM500),於室溫(23℃)下進行。於算出中可使用液滴法,利用注射器製作2μL之液滴並使之接觸於基材,求出自基材表面、液滴、及氣相之三相之接觸點所畫的液滴之切線與液滴-基材界面所成之角度。又,各測定值係分別測定10處之與基材所成之接觸角,並求出其平均值。再者,算出之接觸角係將小數點以後第1位進行四捨五入。 The measurement of the contact angle can be performed at room temperature (23 ° C.) using a contact angle meter (for example, Kyowa Interface Science Co., Ltd., DropMaster DM500). In the calculation, the droplet method can be used, and a 2 μL droplet is made using a syringe and brought into contact with the substrate. The tangent line of the droplet drawn from the contact surface of the substrate, the droplet, and the three phases of the gas phase is obtained. Angle with the droplet-substrate interface. In addition, each measurement value measured the contact angle with the base material at 10 places, and calculated | required the average value. The calculated contact angle is rounded off to the first decimal place.

此處,關於由於接觸角增大而逸氣性提高之情況,可根 據固體與空氣之界面張力下降而進行說明。即,於水接觸於固體之表面時,將固體與空氣之界面張力設為γ1,將水與固體之界面張力設為γ2,將水與空氣之界面張力設為γ3,將氣液界面之切線方向與固液界面之方向所成的角設為θ時,力之平衡係以下述式表示。 Here, regarding the case where the outgassing property is improved due to the increase in contact angle, The explanation is based on the decrease in the interfacial tension between solids and air. That is, when water contacts the surface of a solid, the interfacial tension between solid and air is set to γ1, the interfacial tension between water and solids is set to γ2, the interfacial tension between water and air is set to γ3, and the tangent to the air-liquid interface When the angle formed by the direction and the direction of the solid-liquid interface is θ, the force balance is expressed by the following formula.

γ1=γ3×cosθ+γ2 γ1 = γ3 × cosθ + γ2

此處,θ係接觸角,可藉由使接觸角增大而使γ1降低。 Here, the θ-based contact angle can decrease γ1 by increasing the contact angle.

作為接觸角成為66°以上且125°以下之高分子化合物之例,可舉出:(甲基)丙烯酸系樹脂、烯烴系樹脂、聚矽氧系樹脂、聚氯乙烯系樹脂、聚偏二氯乙烯系樹脂、氟系樹脂、聚酯系樹脂或該等之混合物等。其中,就生產時之成本或成形之容易性、對滅菌處理之耐久性等觀點而言,可較佳地使用聚烯烴系樹脂、聚醯胺系樹脂、氟系樹脂,進而較佳為聚丙烯、聚乙烯、尼龍6、尼龍66及該等之衍生物。尤佳為聚丙烯及其衍生物。 Examples of the polymer compound having a contact angle of 66 ° or more and 125 ° or less include (meth) acrylic resins, olefin resins, polysiloxane resins, polyvinyl chloride resins, and polyvinylidene chloride. Vinyl resin, fluorine resin, polyester resin, or a mixture thereof. Among them, polyolefin-based resins, polyamide-based resins, and fluorine-based resins can be preferably used from the viewpoints of production cost, ease of molding, and durability to sterilization, and polypropylene is more preferable. , Polyethylene, nylon 6, nylon 66 and their derivatives. Especially preferred are polypropylene and its derivatives.

又,作為過濾片之形態,可為多孔體、多孔質體中之任一種,可較佳地使用孔均勻地空著之多孔質體,可舉出篩網、不織布等。其中,就因網眼均勻而血球成分之附著較少,及不易產生自過濾片之溶出物等方面而言,可較佳地使用篩網。 The form of the filter sheet may be any of a porous body and a porous body, and a porous body with pores evenly spaced may be preferably used, and examples thereof include a screen and a nonwoven fabric. Among them, a sieve can be preferably used in terms of less adherence of blood cell components due to uniform meshes, and less occurrence of leachables from the filter sheet.

又,關於過濾片,為了防止局部之逸氣性之惡化,較佳為過濾片整體具有均勻之開口部。此處,所謂過濾片整體具有均勻之開口部,係指如下過濾片,即於開口率不固定之情形時,即便遍及過濾片整體選擇任何之任意5mm見方之範圍,開口率之值之變動範圍亦包含於其平均值之±30%以下,更佳為±18%以下,進而較佳為±10%以下。 Furthermore, in order to prevent deterioration of the outgassing property of the filter sheet, it is preferable that the entire filter sheet has a uniform opening portion. Here, the so-called filter sheet has uniform openings throughout, and refers to a filter sheet in which, when the aperture ratio is not fixed, even if any arbitrary 5 mm square range is selected throughout the entire filter sheet, the variation range of the aperture ratio value It is also included within ± 30% of the average value, more preferably ± 18% or less, and even more preferably ± 10% or less.

作為過濾片之厚度,若變得過厚,則導致管柱內之吸附 體之填充率降低,因此血液淨化效率降低。又,管柱內血液通過時之壓力損失亦增大。另一方面,若過濾片之厚度變得過薄,則過濾片之強度不足,而變得難以使吸附體穩定地保持於套管。根據上述情況,作為過濾片之厚度之上限,較佳為3000μm以下,更佳為成為900μm以下。作為過濾片之厚度之下限,較佳為0.1μm以上,更佳為成為40μm以上。 If the thickness of the filter sheet is too thick, it will cause adsorption in the column The filling rate of the body is reduced, so the blood purification efficiency is reduced. In addition, the pressure loss during the passage of blood in the column also increases. On the other hand, if the thickness of the filter sheet becomes too thin, the strength of the filter sheet becomes insufficient, and it becomes difficult to stably hold the adsorbent body on the sleeve. According to the above, the upper limit of the thickness of the filter is preferably 3000 μm or less, and more preferably 900 μm or less. The lower limit of the thickness of the filter is preferably 0.1 μm or more, and more preferably 40 μm or more.

又,關於保持於管柱內之過濾片,於將其於與管柱內之長軸方向垂直之方向呈開口之部分的表面積設為B1,將其於與管柱內之長軸方向垂直之方向以外呈開口之部分的總表面積設為B2之情形時,較佳為儘量減小B2之面積。亦可認為其原因在於:以利用過濾片使吸附體穩定保持於管柱內為目的,或以將過濾片作為間隔件而提高管柱內流動性等為目的,而使用於與管柱內之長軸方向垂直之方向以外呈開口的過濾片,但此種篩網容易妨礙流經吸附體空隙之空氣之流動,又,容易截留空氣,故而欠佳。又,藉此亦有可填充於管柱內之吸附體量減少,而導致吸附性能降低之可能性。具體而言,較佳為滿足B1/B2≧1.0之關係,更佳為B1/B2≧5.0,進而較佳為B1/B2≧10.0。再者,於不垂直亦不平行於管柱內之長軸方向而是於傾斜方向呈開口之情形時,設為不含於上述分母、分子之任一者中。 Further, regarding the filter piece held in the column, the surface area of the portion which is open in a direction perpendicular to the long axis direction in the column is set to B1, and the surface area of the filter piece is set to be perpendicular to the long axis direction in the column. In the case where the total surface area of the portion that is open outside the direction is set to B2, it is preferable to reduce the area of B2 as much as possible. The reason may be considered to be used for the purpose of stably holding the adsorbent in the column with a filter sheet, or to improve the fluidity in the column with the filter sheet as a spacer, etc. Filters with openings other than the direction perpendicular to the long axis, but such screens are likely to hinder the flow of air flowing through the gap of the adsorbent, and it is easy to trap air, which is not good. In addition, there is a possibility that the amount of the adsorbable body that can be filled in the pipe string is reduced, resulting in a decrease in the adsorption performance. Specifically, it is preferable to satisfy the relationship of B1 / B2 ≧ 1.0, more preferably B1 / B2 ≧ 5.0, and even more preferably B1 / B2 ≧ 10.0. In addition, when the opening is not perpendicular or parallel to the long axis direction in the column but is inclined in the oblique direction, it is assumed that it is not included in any of the above denominator and numerator.

作為配置有過濾片之管柱之形態,通常包含:設置有淨化前之血流流入之入口部與淨化後之血流排出之出口部的套管;收容於套管中之吸附體;設置於入口部及/或出口部之內側之過濾片;及設置有於套管長度方向之兩端所配置之血液之流入口、流出口的集管頭蓋。過濾片較佳為於使吸附體保持於套管內之關係上,分別設置於入口及出口之兩側,於可僅以入口、出口之任一側保持吸附體之情形時, 可單獨使用,亦可於管柱之單側配置本發明之過濾片,於相反側配置與本發明不同之過濾片。 As a form of a column equipped with a filter sheet, it usually includes: a sleeve provided with an inlet portion where blood flow before purification and an outlet portion where blood flow is discharged after purification; an adsorbent housed in the sleeve; A filter sheet inside the inlet and / or outlet; and a header cover provided with blood inlets and outlets arranged at both ends in the length direction of the cannula. The filter sheet is preferably arranged on both sides of the inlet and the outlet in a manner that the adsorbent is held in the sleeve, and when the adsorbent can be held on only one side of the inlet and the outlet, It can be used alone, or the filter sheet of the present invention can be arranged on one side of the column, and the filter sheet different from the present invention can be arranged on the opposite side.

作為管柱之套管內之吸附體之填充率之上限,較佳為未滿70%,進而較佳為成為63%以下。作為吸附體之填充率之下限,較佳為13%以上,進而較佳為30%以上,尤佳為成為45%以上。藉由將吸附體之填充率設為13%以上,而使血液淨化所必需之血液量降低,因此可減輕患者之負擔。另一方面,若吸附體之填充率成為70%以上,則逸氣性惡化。又,因變得不易填充吸附體,故導致作業效率降低。再者,此處所謂填充率,係指吸附體體積於設置有淨化前之血流流入之入口部與淨化後之血流排出之出口部之套管體積中所占的比例,且不包括上述集管部等。 The upper limit of the filling rate of the adsorbent in the sleeve of the pipe string is preferably less than 70%, and more preferably 63% or less. The lower limit of the filling rate of the adsorbent is preferably 13% or more, more preferably 30% or more, and even more preferably 45% or more. By setting the filling rate of the adsorbent to 13% or more, the amount of blood necessary for blood purification is reduced, and thus the burden on the patient can be reduced. On the other hand, when the filling rate of the adsorbed body is 70% or more, the outgassing property is deteriorated. In addition, since it becomes difficult to fill the adsorbent, work efficiency is reduced. In addition, the filling rate here refers to the ratio of the volume of the adsorbent to the volume of the cannula provided with the inlet portion in which the blood flow before the purification is provided and the outlet portion where the blood flow is discharged after the purification, and does not include the above. Collecting department, etc.

關於本發明之血液淨化管柱之製作例,於以下表示使用纖維形狀為實心纖維者之一例,但本發明並不限定於此。 Regarding an example of producing the blood purification tube string of the present invention, an example in which a fiber shape is used as a solid fiber is shown below, but the present invention is not limited to this.

製備使聚合體溶解於溶劑中而成之紡絲原液。紡絲原液係自具有圓形之原液吐出口之噴嘴吐出,利用凝固浴而凝固成實心纖維形狀。凝固浴通常包含水或醇等凝固劑、或者與構成紡絲原液之溶劑之混合物。又,可藉由控制凝固浴之溫度而使空隙率變化。空隙率可受到紡絲原液之種類等影響,因此凝固浴之溫度亦為適當選擇者,但通常可藉由提高凝固浴溫度而使空隙率變高。該機制尚不明確,但可認為或許其原因在於:於自原液之脫溶劑與凝固收縮之競爭反應中,於高溫浴中脫溶劑較快,從而於收縮前被凝固固定。然而,若凝固浴溫度變得過高,則細孔徑變得過大,因此例如實心纖維為含有聚甲基丙烯酸甲酯(以下,稱為PMMA)之纖維,且於內管加入氣體之情形之凝固浴溫度較佳為39℃以上,更佳為42℃以上。另一方面,較佳 為50℃以下,更佳為46℃以下。 A spinning dope prepared by dissolving a polymer in a solvent is prepared. The spinning dope is discharged from a nozzle having a round dope outlet and is coagulated into a solid fiber shape by a coagulation bath. The coagulation bath usually contains a coagulant such as water or alcohol, or a mixture with a solvent constituting the spinning dope. In addition, the porosity can be changed by controlling the temperature of the coagulation bath. The porosity can be affected by the type of spinning dope, etc., so the temperature of the coagulation bath is also an appropriate choice, but usually the porosity can be increased by increasing the temperature of the coagulation bath. The mechanism is not clear, but it may be considered that the reason may be that in the competitive reaction between desolvation from the original solution and coagulation and shrinkage, the desolvation is faster in a high-temperature bath, so that it is solidified and fixed before shrinking. However, if the temperature of the coagulation bath becomes too high, the pore diameter becomes too large. Therefore, for example, solid fibers are fibers containing polymethyl methacrylate (hereinafter referred to as PMMA), and solidification in the case where gas is added to the inner tube. The bath temperature is preferably 39 ° C or higher, and more preferably 42 ° C or higher. On the other hand, better The temperature is 50 ° C or lower, more preferably 46 ° C or lower.

其次,通過將附著於凝固之實心纖維之溶劑洗淨之步驟。將實心纖維洗淨之手段並無特別限定,可較佳地使用如下方法,即,使實心纖維通過多段之裝滿水之浴(稱為水洗浴)中。水洗浴中之水之溫度只要根據構成纖維之聚合體之性質決定即可。例如於為含有PMMA之纖維之情形時,可使用30~50℃。 Next, a step of washing the solvent adhered to the solidified solid fibers is performed. The method of washing the solid fibers is not particularly limited, and a method may be preferably used in which the solid fibers are passed through a multi-stage bath filled with water (referred to as a water bath). The temperature of the water in the water bath may be determined according to the properties of the polymer constituting the fiber. For example, in the case of PMMA-containing fibers, 30 to 50 ° C can be used.

又,為了於水洗浴後保持實心纖維之孔徑,亦可加入賦予實心纖維保濕成分之步驟。此處所謂保濕成分,係指可保持實心纖維之濕度之成分,或者於空氣中可防止實心纖維之濕度降低之成分。作為保濕成分之代表例,有甘油或其水溶液等。 In addition, in order to maintain the pore diameter of the solid fiber after bathing in water, a step of imparting a moisturizing component to the solid fiber may be added. The moisturizing component herein refers to a component that can maintain the humidity of solid fibers or a component that prevents the humidity of solid fibers from decreasing in the air. Typical examples of moisturizing ingredients include glycerin or an aqueous solution thereof.

於水洗或保濕成分賦予結束後,為了提高收縮性較高之實心纖維之尺寸穩定性,亦可通過裝滿經加熱之保濕成分之水溶液之浴(稱為熱處理浴)之步驟。於熱處理浴中裝滿經加熱之保濕成分之水溶液,並使實心纖維通過該熱處理浴,藉此受到熱之作用而收縮,從而於以後之步驟中變得不易收縮,而可使纖維構造穩定。此時之熱處理溫度根據纖維素材而不同,於包含PMMA之纖維之情形時,較佳為75℃以上,更佳為82℃以上。又,設定為較佳為90℃以下,更佳為86℃以下之溫度。 After the washing or the moisturizing ingredient is given, in order to improve the dimensional stability of solid fibers with high shrinkage, a bath filled with an aqueous solution of the heated moisturizing ingredient (called a heat treatment bath) may be used. The heat treatment bath is filled with an aqueous solution of the heated moisturizing ingredient, and the solid fibers are passed through the heat treatment bath, thereby being contracted by the effect of heat, so that it becomes difficult to shrink in the subsequent steps, and the fiber structure can be stabilized. The heat treatment temperature at this time varies depending on the fiber material. In the case of PMMA-containing fibers, the temperature is preferably 75 ° C or higher, and more preferably 82 ° C or higher. The temperature is preferably 90 ° C or lower, and more preferably 86 ° C or lower.

若表示使用所獲得之實心纖維而製成淨化管柱之手段之一例,則如下所述。 An example of a method for purifying a pipe string using the obtained solid fiber is as follows.

首先,將實心纖維切割成必需之長度,將必需根數打成捆後,放入至成為血液淨化管柱之筒部分之塑膠套管中。其後,利用切割器等將實心纖維之兩端以實心纖維收於套管內之方式切斷,於管柱兩端之管柱兩側端面之被處理液之流出入口安裝如圖1所示般,切 割成與內徑相同直徑之篩網過濾片。最後安裝被稱為集管頭蓋之被處理液之入口、出口端口,而可獲得血液淨化管柱。 First, the solid fiber is cut to a necessary length, the necessary number is bundled, and then it is put into a plastic sleeve which becomes the barrel portion of the blood purification tube string. Thereafter, the two ends of the solid fiber are cut by means of a cutter or the like so that the solid fiber is received in the casing, and the outflow inlets of the treated liquid at the two end surfaces of the both ends of the column are installed as shown in Figure 1. Like, cut Cut into a mesh filter with the same diameter as the inner diameter. Finally, the inlet and outlet ports of the liquid to be treated, which is called a header head cover, are installed to obtain a blood purification tube string.

又,於用於醫療用具等時,較佳為進行殺菌或滅菌而使用。作為殺菌、滅菌方法,可例示各種殺菌、滅菌方法,例如高壓蒸氣滅菌、γ射線滅菌、環氧乙烷氣體滅菌、藥劑殺菌、紫外線殺菌等。該等方法中,γ射線滅菌、高壓蒸氣滅菌、環氧乙烷氣體滅菌對滅菌效率與材料之影響較少,故而較佳。 Moreover, when it is used for a medical appliance etc., it is preferable to use for sterilization or sterilization. Examples of the sterilization and sterilization methods include various sterilization and sterilization methods such as high-pressure steam sterilization, γ-ray sterilization, ethylene oxide gas sterilization, pharmaceutical sterilization, and ultraviolet sterilization. Among these methods, γ-ray sterilization, high-pressure steam sterilization, and ethylene oxide gas sterilization have less influence on sterilization efficiency and materials, and are therefore preferred.

作為本發明中之血液淨化管柱之使用形態,就1次之處理量或操作之簡便性等觀點而言,較佳為如下方法,即安裝於體外循環迴路而於線上進行吸附去除。於該情形時,可單獨使用本發明之淨化管柱,亦可於透析時等與人工腎臟等直列連接而同時使用。 As the use form of the blood purification tube string in the present invention, from the viewpoints of a single treatment amount and ease of operation, a method is preferred in which it is mounted on an extracorporeal circulation circuit and is adsorbed and removed on-line. In this case, the purification column of the present invention may be used alone, or it may be used in parallel with an artificial kidney or the like during dialysis.

[實施例] [Example] [實施例1] [Example 1]

將重量平均分子量為40萬之syn-PMMA 31.7重量份、重量平均分子量為140萬之syn-PMMA 31.7重量份、重量平均分子量為50萬之iso-PMMA 16.7重量份、含有對苯乙烯磺酸鈉1.5mol%之分子量30萬之PMMA共聚合體20重量份與二甲基亞碸376重量份進行混合,於110℃下攪拌8小時而製備紡絲原液。獲得之紡絲原液於110℃下之黏度為1240 poise。將獲得之紡絲原液自保溫在93℃之具有直徑0.3mm之圓形吐出口之噴嘴以1.0g/min之速度吐出至空氣中,於空中部分移行50cm後,導至凝固浴中。將凝固浴所使用之水溫(凝固浴溫度)設為42℃而獲得實心纖維。將各實心纖維水洗後,以70重量%之水溶液之形式賦予甘油作為保濕劑後,將熱處理浴溫度設為84℃,將多餘之甘 油去除後,捲繞間隔纖維並以42m/min進行捲取。獲得之實心纖維之纖維直徑係使用Nikon公司製造之投影機V-10A進行測定,結果為121μm。 31.7 parts by weight of syn-PMMA with a weight average molecular weight of 400,000, 31.7 parts by weight of syn-PMMA with a weight average molecular weight of 1.4 million, 16.7 parts by weight of iso-PMMA with a weight average molecular weight of 500,000, and containing sodium p-styrene sulfonate 20 parts by weight of 1.5 mol% PMMA copolymer having a molecular weight of 300,000 was mixed with 376 parts by weight of dimethyl sulfene, and stirred at 110 ° C. for 8 hours to prepare a spinning dope. The obtained spinning dope had a viscosity of 1240 poise at 110 ° C. The obtained spinning dope was discharged into the air at a speed of 1.0 g / min from a nozzle having a circular discharge port having a diameter of 0.3 mm kept at 93 ° C, and after traveling 50 cm in the air, it was guided to a coagulation bath. A solid fiber was obtained by setting the water temperature (coagulation bath temperature) used in the coagulation bath to 42 ° C. After each solid fiber was washed with water, glycerin was added as a moisturizing agent in the form of a 70% by weight aqueous solution, and then the temperature of the heat treatment bath was set to 84 ° C. After the oil was removed, the spacer fibers were wound and wound up at 42 m / min. The fiber diameter of the obtained solid fiber was measured using a projector V-10A manufactured by Nikon Corporation, and it was 121 μm.

使用公知之方法將獲得之實心纖維打成捆,於內徑38mm、軸方向長度133mm之聚碳酸酯製圓筒狀套管內,以填充率成為57%之方式內藏纖維直徑121μm之實心纖維。其次,於該管柱之兩側端面之被處理液之流出入口安裝如圖1所示般,切割成與套管內徑同等之直徑之網眼當量直徑84μm、開口率36%之聚丙烯製篩網過濾片。再者,過濾片網眼之當量直徑、開口率、管柱之填充率係使用Nikon公司製造之投影機V-10A進行測定,並利用上述之各種方法算出。 The obtained solid fibers were bundled by a known method, and a solid fiber having a diameter of 121 μm was embedded in a polycarbonate cylindrical sleeve having an inner diameter of 38 mm and an axial length of 133 mm so that the filling ratio became 57%. . Second, install the outflow inlets of the liquid to be treated on both sides of the tubing string as shown in Figure 1. Polypropylene made of a mesh equivalent diameter of 84 μm and an opening ratio of 36% cut to the same diameter as the inner diameter of the sleeve Screen filter. In addition, the equivalent diameter of the mesh of the filter, the aperture ratio, and the filling rate of the column were measured using a projector V-10A manufactured by Nikon Corporation, and calculated by various methods described above.

進而,於管柱兩端配置具備被處理液之流入口及流出口之集管頭蓋,其次利用純水將管柱內部洗淨後,利用蓋將各端口密封,而製作於兩側安裝有篩網之管柱。該管柱之吸附體空隙之平均圓當量直徑為91μm。將該管柱以其長度方向垂直於地面之方式安裝於如圖2之逸氣性試驗用迴路中,並以下述程序對被篩網截留之管柱內空氣之去除率進行測定。 Furthermore, a header head cap provided with an inlet and an outlet of the liquid to be treated is arranged at both ends of the column, and then the inside of the column is washed with pure water, and then each port is sealed with the cap, and screens are installed on both sides. The column of the net. The average circular equivalent diameter of the adsorbent voids of this column was 91 μm. This pipe string was installed in the circuit for the gas escape test as shown in Fig. 2 with its length direction perpendicular to the ground, and the removal rate of air in the pipe string trapped by the screen was measured by the following procedure.

(1)使用泵,使純水以流速100ml/s進行循環直至迴路內之空氣完全逃逸。根據需要對管柱進行敲打等而施加衝擊,藉此容易將空氣逐出。 (1) Use a pump to circulate pure water at a flow rate of 100 ml / s until the air in the circuit completely escapes. If necessary, an impact is applied to the pipe string, and the air is easily expelled.

(2)停止泵,一面注意不要使空氣混入一面將管柱自迴路取下,分別於被處理液之流入口及流出口蓋上蓋。測定此時之管柱重量,設為A。 (2) Stop the pump, while taking care not to mix air, remove the pipe string from the circuit, and cover the inlet and outlet of the liquid to be treated respectively. The column weight at this time was measured and set to A.

(3)將重量測定後之管柱再次裝回迴路中,使純水以流速100ml/s進行循環。 (3) The column after the weight measurement is put back into the circuit again, and the pure water is circulated at a flow rate of 100 ml / s.

(4)從自管柱之被處理液流入口至迴路之上游部1cm處,使用注射器歷時5秒鐘注入10ml之乾燥空氣。 (4) From the inlet of the liquid to be treated of the column to the upstream of the circuit 1 cm, use a syringe to inject 10 ml of dry air for 5 seconds.

(5)直接以流速100ml/s使純水循環1分鐘。該期間,迴路為靜置之狀態。 (5) Circulate pure water directly at a flow rate of 100 ml / s for 1 minute. During this period, the circuit is in a static state.

(6)停止泵,一面注意不要使空氣混入一面將管柱自迴路取下,分別於被處理液之流入口及流出口蓋上蓋。測定此時之管柱重量,設為B。 (6) Stop the pump, while taking care not to mix air, remove the pipe string from the circuit, and cover the inlet and outlet of the liquid to be treated respectively. The column weight at this time was measured, and it was set to B.

(7)根據下述式算出管柱內空氣去除率。將結果示於表1。 (7) Calculate the air removal rate in the column according to the following formula. The results are shown in Table 1.

管柱內空氣去除率(%)=(A-B)/A×100。 Air removal rate in the column (%) = (A-B) / A × 100.

[實施例2] [Example 2]

將紡絲原液之吐出速度設為1.9g/min,藉此使纖維直徑成為181μm,除此以外,利用與實施例1相同之方法而獲得實心纖維,於與實施例1相同之尺寸、形狀之套管內,以與實施例1相同之方式內藏獲得之實心纖維,且於套管兩側端面,同樣地配置與實施例1相同之尺寸、形狀之篩網過濾片、集管頭蓋。該管柱之吸附體空隙之平均圓當量直徑為135μm。針對該管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表1。 A solid fiber was obtained by the same method as in Example 1 except that the spinning speed of the spinning dope was set to 1.9 g / min, thereby setting the fiber diameter to 181 μm. In the sleeve, solid fibers obtained in the same manner as in Example 1 were built-in, and the same size and shape of screen filters and header caps as in Example 1 were arranged on the end faces on both sides of the sleeve. The average circular equivalent diameter of the adsorbent voids of this column was 135 μm. For this pipe string, the same procedure as in Example 1 was used to measure the air removal rate in the pipe string. The results are shown in Table 1.

[實施例3] [Example 3]

將紡絲原液之吐出速度設為0.5g/min,藉此使纖維直徑成為56μm,除此以外,利用與實施例1相同之方法而獲得實心纖維,於與實施例1相同之尺寸、形狀之套管內,以與實施例1相同之方式內藏獲得之實心纖維,且於套管兩側端面,同樣地配置與實施例1相同之尺寸、形狀之篩網過濾片、集管頭蓋。該管柱之吸附體空隙之平均圓當 量直徑為42μm。針對該管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表1。 Except that the spinning speed of the spinning dope was set to 0.5 g / min, thereby setting the fiber diameter to 56 μm, a solid fiber was obtained by the same method as in Example 1. In the sleeve, solid fibers obtained in the same manner as in Example 1 were built-in, and the same size and shape of screen filters and header caps as in Example 1 were arranged on the end faces on both sides of the sleeve. The average circle diameter of the adsorbent voids of the column The gauge diameter is 42 μm. For this pipe string, the same procedure as in Example 1 was used to measure the air removal rate in the pipe string. The results are shown in Table 1.

[實施例4] [Example 4]

利用與實施例1相同之方法而獲得實心纖維,於與實施例1相同之尺寸、形狀之套管內,以與實施例1相同之方式內藏獲得之實心纖維,且於套管兩側端面,與實施例1同樣地配置網眼當量直徑124μm、開口率31%之聚丙烯製篩網過濾片、及與實施例1相同之尺寸、形狀之集管頭蓋。該管柱之吸附體空隙之平均圓當量直徑為91μm。針對該管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表1。又,為了對獲得之淨化管柱之蛋白質去除性能進行評價,而利用以下所示之方法進行β2-MG(微球蛋白)之清除率測定。將結果示於表3。 The solid fibers were obtained by the same method as in Example 1. The solid fibers obtained in the same size and shape as in Example 1 were embedded in the same way as in Example 1. In the same manner as in Example 1, a polypropylene mesh filter with a mesh equivalent diameter of 124 μm and an opening ratio of 31%, and a header cap of the same size and shape as in Example 1 were arranged. The average circular equivalent diameter of the adsorbent voids of this column was 91 μm. For this pipe string, the same procedure as in Example 1 was used to measure the air removal rate in the pipe string. The results are shown in Table 1. In addition, in order to evaluate the protein removal performance of the obtained purification column, β 2 -MG (microglobulin) clearance was measured by the method shown below. The results are shown in Table 3.

β2-MG之清除率之測定方法 Method for measuring β 2 -MG clearance

作為吸附管柱之性能評價,對β2-MG之清除率進行測定。已知β2-MG係作為長期透析併發症之透析相關性類澱粉變性症之原因蛋白質。 As a performance evaluation of the adsorption column, the clearance of β 2 -MG was measured. Β 2 -MG is known as a cause protein of dialysis-related amyloidosis due to long-term dialysis complications.

針對添加有乙二胺四乙酸二鈉之牛血液,以血容比成為30±3%,總蛋白質量成為6.5±0.5g/dL之方式進行調整。使用採血後5天以內之牛血液。 For cow blood to which disodium ethylenediamine tetraacetate was added, the blood volume ratio was adjusted to 30 ± 3%, and the total protein mass was adjusted to 6.5 ± 0.5g / dL. Use cattle blood within 5 days after blood collection.

其次,以β2-MG濃度成為1mg/l之方式進行添加並攪拌。對該牛血液進行如下分類,即將其中2L作為循環用,將其中1.5L作為清除率測定用。 Next, the β 2 -MG concentration was added and stirred so that the concentration became 1 mg / l. The bovine blood was classified as follows, that is, 2 L was used for circulation, and 1.5 L was used for measurement of clearance.

迴路係如圖5般進行設置。迴路中,將取入被處理液之液入口部設為Bi,將血液淨化管柱通液後之液出口部設為Bo。 The circuit is set up as shown in Figure 5. In the circuit, the liquid inlet portion that takes in the liquid to be treated is set to Bi, and the liquid outlet portion after the blood purification tube string is passed through the liquid is set to Bo.

將Bi放入加入了於上述調整之牛血液2L(37℃)之循環用燒杯內,將流速設為200mL/min,將泵啟動,將自Bo排出之液體90秒鐘份廢棄後,立即將Bo放入循環用燒杯內而設為循環狀態。 Put Bi into a circulation beaker containing 2L of beef blood (37 ° C) adjusted above, set the flow rate to 200 mL / min, start the pump, and discard 90 seconds of the liquid discharged from Bo. Immediately Bo was put into a circulation beaker and set to a circulation state.

進行循環1小時後停止泵。 Stop the pump after 1 hour of cycling.

其次,將Bi放入於上述調整之清除率測定用之牛血液內,並將Bo放入廢棄用燒杯內。 Next, Bi was placed in the bovine blood for the above-mentioned adjusted clearance measurement, and Bo was placed in a beaker for disposal.

流速係設為200mL/min,將泵啟動後經過2分鐘,其後自清除率測定用之牛血液(37℃)採取樣本10ml,設為Bi液。於啟動後經過4分鐘30秒,其後採取自Bo流出之樣本10ml,設為Bo液。該等樣本係保存於-20℃以下之冷凍庫中。 The flow rate was set to 200 mL / min, and 2 minutes after the pump was started, 10 ml of a sample was taken from the bovine blood (37 ° C.) for measuring the clearance, and the solution was set to Bi. After 4 minutes and 30 seconds elapsed after starting, 10 ml of a sample flowing from Bo was taken as the Bo solution. These samples are stored in a freezer below -20 ° C.

藉由下述I式,由各液之β2-MG濃度算出清除率。有測定值根據牛血液之批次而不同之情形,因此於實施例、比較例中全部使用同一批次之牛血液。 The clearance was calculated from the β 2 -MG concentration of each solution by the following formula I. Since the measured value may vary depending on the lot of bovine blood, the same lot of bovine blood is used in the examples and comparative examples.

Co(ml/min)=(CBi-CBo)×QB/CBi (I) Co (ml / min) = (CBi-CBo) × Q B / CBi (I)

I式中,Co2-MG清除率(ml/min),CBi=Bi液中之β2-MG濃度、CBo=Bo液中之β2-MG濃度、QB=Bi泵流量(ml/min)。 In formula I, C o = β 2 -MG clearance (ml / min), CBi = 2 -MG concentration of Bi liquid β, CB o = 2 -MG concentration Bo solution of β, Q B = Bi pump flow (ml / min).

[實施例5] [Example 5]

利用與實施例1相同之方法而獲得實心纖維,於與實施例1相同之尺寸、形狀之套管內,以與實施例1相同之方式內藏獲得之實心纖維,且於套管兩側端面,與實施例1同樣地配置網眼當量直徑108μm、開口率40%之聚對苯二甲酸乙二酯製篩網過濾片、及與實施例1相同之尺寸、形狀之集管頭蓋。該管柱之吸附體空隙之平均圓當量直徑為91μm。針對該管柱,以與實施例1相同之程序測定管柱內空氣去除率。 將結果示於表1。又,以與實施例4相同之程序測定β2-MG清除率。將結果示於表3。 The solid fibers were obtained by the same method as in Example 1. The solid fibers obtained in the same size and shape as in Example 1 were embedded in the same way as in Example 1. In the same manner as in Example 1, a polyethylene terephthalate screen filter with a mesh equivalent diameter of 108 μm and an opening ratio of 40%, and a header cap of the same size and shape as in Example 1 were arranged. The average circular equivalent diameter of the adsorbent voids of this column was 91 μm. For this pipe string, the same procedure as in Example 1 was used to measure the air removal rate in the pipe string. The results are shown in Table 1. The β 2 -MG clearance was measured by the same procedure as in Example 4. The results are shown in Table 3.

[實施例6] [Example 6]

將紡絲原液之吐出速度設為4.7g/min,藉此使纖維直徑成為260μm,除此以外,利用與實施例1相同之方法而獲得實心纖維,於與實施例1相同之尺寸、形狀之套管內,以與實施例1相同之方式內藏獲得之實心纖維,且與實施例5同樣地,於套管兩側端面,與實施例1同樣地配置網眼當量直徑108μm、開口率40%之聚丙烯製篩網過濾片、及與實施例1相同之尺寸、形狀之集管頭蓋。該管柱之吸附體空隙之平均圓當量直徑為194μm。針對該管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表1。又,以與實施例4相同之程序測定β2-MG清除率。將結果示於表3。 A solid fiber was obtained by the same method as in Example 1 except that the spinning speed of the spinning dope was set to 4.7 g / min, thereby setting the fiber diameter to 260 μm. In the sleeve, solid fibers obtained in the same manner as in Example 1 were embedded, and in the same manner as in Example 5, the mesh equivalent diameter of 108 μm and the aperture ratio of 40 were arranged on the both end faces of the sleeve as in Example 1. % Polypropylene mesh filter sheet, and a header cap of the same size and shape as in Example 1. The average circular equivalent diameter of the adsorbent voids of this column was 194 μm. For this pipe string, the same procedure as in Example 1 was used to measure the air removal rate in the pipe string. The results are shown in Table 1. The β 2 -MG clearance was measured by the same procedure as in Example 4. The results are shown in Table 3.

[比較例1] [Comparative Example 1]

將紡絲原液之吐出速度設為4.7g/min,藉此使纖維直徑成為260μm,除此以外,利用與實施例1相同之方法而獲得實心纖維,於與實施例1相同之尺寸、形狀之套管內,以與實施例1相同之方式內藏獲得之實心纖維,且於套管兩側端面,同樣地配置與實施例1相同之尺寸、形狀之篩網過濾片、集管頭蓋。該管柱之吸附體空隙之平均圓當量直徑為194μm。針對該管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表1。又,以與實施例4相同之程序測定β2-MG清除率。將結果示於表3。 A solid fiber was obtained by the same method as in Example 1 except that the spinning speed of the spinning dope was set to 4.7 g / min, thereby setting the fiber diameter to 260 μm. In the sleeve, solid fibers obtained in the same manner as in Example 1 were built-in, and the same size and shape of screen filters and header caps as in Example 1 were arranged on the end faces on both sides of the sleeve. The average circular equivalent diameter of the adsorbent voids of this column was 194 μm. For this pipe string, the same procedure as in Example 1 was used to measure the air removal rate in the pipe string. The results are shown in Table 1. The β 2 -MG clearance was measured by the same procedure as in Example 4. The results are shown in Table 3.

[實施例7] [Example 7]

將與實施例1相同之紡絲原液自保溫在93℃之環狀狹縫部分之外 徑/內徑=2.1/1.95mm 之雙管中空纖維用噴嘴,以2.5g/min之速度吐出至空氣中。此處,同時向雙管之內管部分注入氮氣,於空中部分移行50cm後,導至凝固浴中。將凝固浴所使用之水溫(凝固浴溫度)設為42℃而獲得中空纖維膜。將各中空纖維膜水洗後,以70重量%之水溶液之形式賦予甘油作為保濕劑後,將熱處理浴溫度設為84℃,將多餘之甘油去除後,捲繞間隔纖維並以60m/min進行捲取。獲得之中空纖維之纖維直徑係使用Nikon公司製造之投影機V-10A進行測定,結果內徑為200μm,纖維外徑為260μm。於與實施例1相同之尺寸、形狀之套管內,以與實施例1相同之方式內藏獲得之中空纖維,與實施例6同樣地,於套管兩側端面,與實施例1同樣地配置網眼當量直徑108μm、開口率40%之聚丙烯製篩網過濾片、及與實施例1相同之尺寸、形狀之集管頭蓋。該管柱之吸附體空隙之平均圓當量直徑為195μm。針對該管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表1。 The same spinning dope as in Example 1 was used. The outer diameter / inner diameter of the annular slit portion kept at 93 ° C was 2.1 / 1.95mm. The double-tube hollow fiber nozzle is discharged into the air at a speed of 2.5 g / min. Here, nitrogen is injected into the inner tube portion of the double tube at the same time, and after moving 50 cm in the air, it is led to the coagulation bath. A hollow fiber membrane was obtained by setting the water temperature (coagulation bath temperature) used in the coagulation bath to 42 ° C. Each hollow fiber membrane was washed with water, and glycerin was added as a humectant in the form of a 70% by weight aqueous solution. The heat treatment bath temperature was set to 84 ° C. After removing excess glycerin, the spacer fibers were wound and rolled at 60 m / min take. The fiber diameter of the obtained hollow fiber was measured using a projector V-10A manufactured by Nikon Corporation. As a result, the inner diameter was 200 μm and the fiber outer diameter was 260 μm. The hollow fiber having the same size and shape as in Example 1 was embedded in the same way as in Example 1. The hollow fibers were obtained in the same manner as in Example 6. At the end faces on both sides of the sleeve, the same as in Example 1. A polypropylene mesh filter with a mesh equivalent diameter of 108 μm and an opening ratio of 40%, and a header cap of the same size and shape as in Example 1 were provided. The average circular equivalent diameter of the adsorbent voids of this column was 195 μm. For this pipe string, the same procedure as in Example 1 was used to measure the air removal rate in the pipe string. The results are shown in Table 1.

[參考例1] [Reference Example 1]

於內徑46mm、軸方向長度100mm之圓筒狀套管之被處理液流出側端面,如圖2所示般安裝切割成與被處理液之流出口之內徑相同直徑之圓柱狀的網眼當量直徑326μm、開口率51%之聚丙烯製篩網過濾片。進而,將具備被處理液之流入口及流出口之集管頭蓋配置於兩端,而製作單側安裝篩網之管柱。再者,不內藏吸附體。針對該單側安裝篩網之管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表2。 At the end face of the treated liquid outflow side of the cylindrical sleeve with an inner diameter of 46 mm and a length of 100 mm in the axial direction, a cylindrical mesh cut into the same diameter as the inner diameter of the outlet of the treated liquid is installed as shown in FIG. 2. Polypropylene mesh filter with an equivalent diameter of 326 μm and an aperture ratio of 51%. Furthermore, a header head having an inlet and an outlet for the liquid to be treated was arranged at both ends, and a column with a screen mounted on one side was produced. Furthermore, no adsorbent is built in. With respect to the single-sidedly installed mesh screen, the same procedure as in Example 1 was used to determine the air removal rate in the string. The results are shown in Table 2.

[參考例2] [Reference Example 2]

於與參考例1相同之尺寸、形狀之套管之被處理液流出側端面,安裝切割成與被處理液之流出口之內徑相同直徑之圓柱狀的網眼當量直徑274μm、開口率45%、厚度245mm之聚四氟乙烯製篩網過濾片,除此以外,以與參考例1相同之方式製作單側安裝篩網之管柱。針對該單側安裝篩網之管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表2。 On the end face of the treated liquid outflow side of the casing of the same size and shape as in Reference Example 1, a cylindrical mesh with an equivalent diameter of 274 μm and an opening ratio of 45% cut to the same diameter as the inner diameter of the outlet of the treated liquid was installed. With the exception of a PTFE mesh filter with a thickness of 245 mm, a single-sided screen mesh column was fabricated in the same manner as in Reference Example 1. With respect to the single-sidedly installed mesh screen, the same procedure as in Example 1 was used to determine the air removal rate in the string. The results are shown in Table 2.

[參考例3] [Reference Example 3]

於與參考例1相同之尺寸、形狀之套管之被處理液流出側端面,安裝切割成與被處理液之流出口之內徑相同直徑之圓柱狀的網眼當量直徑274μm、開口率37%、厚度291mm之尼龍66製篩網過濾片,除此以外,以與參考例1相同之方式製作單側安裝篩網之管柱。針對該單側安裝篩網之管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表2。 On the end face of the treated liquid outflow side of the casing of the same size and shape as in Reference Example 1, a cylindrical mesh with an equivalent diameter of 274 μm and an opening ratio of 37% cut into the same diameter as the inner diameter of the outlet of the treated liquid was installed. With the exception of a 291-mm-thick nylon 66 mesh filter, the same method as in Reference Example 1 was used to make a pipe string with a single-sided screen. With respect to the single-sidedly installed mesh screen, the same procedure as in Example 1 was used to determine the air removal rate in the string. The results are shown in Table 2.

[參考例4] [Reference Example 4]

於與參考例1相同之尺寸、形狀之套管之被處理液流出側端面,安裝切割成與被處理液之流出口之內徑相同直徑之圓柱狀的網眼當量直徑308μm、開口率42%、厚度280mm之聚對苯二甲酸乙二酯製篩網過濾片,除此以外,以與參考例1相同之方式製作單側安裝篩網之管柱。針對該單側安裝篩網之管柱,以與實施例1相同之程序測定管柱內空氣去除率。將結果示於表2。 On the end face of the treated liquid outflow side of the casing of the same size and shape as in Reference Example 1, a cylindrical mesh with an equivalent diameter of 308 μm and an opening ratio of 42% cut into the same diameter as the inner diameter of the outlet of the treated liquid was installed. Except for a polyethylene mesh filter sheet having a thickness of 280 mm, a single-sided screen mesh column was manufactured in the same manner as in Reference Example 1 except for this. With respect to the single-sidedly installed mesh screen, the same procedure as in Example 1 was used to determine the air removal rate in the string. The results are shown in Table 2.

根據表1之結果可知,若網眼之當量直徑相對於管柱內吸附體空隙之平均圓當量直徑的比例為45%以上,則管柱內空氣去除率可獲得較高之值,若未滿45%,則管柱內空氣去除率顯示59%之較低值。可認為其原因在於:於過濾片網眼之當量直徑小於管柱內吸附體空隙之平均圓當量直徑之情形時,相對於通過管柱內之空氣之截面面積,過濾片之網眼明顯較小,因此空氣容易被過濾片截留。再者,與聚對苯二甲酸乙二酯製之篩網相比,聚丙烯製之篩網顯示略高之空氣去除率。 According to the results in Table 1, it can be seen that if the ratio of the equivalent diameter of the mesh to the average circular equivalent diameter of the voids of the adsorbent in the column is more than 45%, the air removal rate in the column can obtain a higher value. 45%, the air removal rate in the column shows a lower value of 59%. It can be considered that the reason is that when the equivalent diameter of the mesh of the filter is smaller than the average circular equivalent diameter of the gap of the adsorbent in the column, the mesh of the filter is significantly smaller than the cross-sectional area of the air passing through the column. Therefore, the air is easily trapped by the filter. Furthermore, compared to polyethylene mesh screens, polypropylene mesh screens show slightly higher air removal rates.

根據表2之結果可知,即便使用開口率與網眼當量直徑大致同等之篩網,亦接觸角越高,管柱內空氣去除率顯示越高之值。可認為其原因在於:可藉由使接觸角變大而使固體與空氣之界面張力降低。 From the results in Table 2, it can be seen that even if a sieve having an opening ratio approximately equal to the mesh equivalent diameter is used, the higher the contact angle, the higher the air removal rate in the column. The reason is considered to be that the interface tension between the solid and air can be reduced by increasing the contact angle.

根據表3之結果可知,關於吸附體之纖維直徑、填充率同等之管 柱,管柱內空氣去除率與β2-MG清除率之關係有管柱內空氣去除率越低,β2-MG之清除率越降低之傾向,即蛋白質之吸附性能越降低之傾向。再者,於表3之結果中,實施例4及實施例5之管柱之吸附體之纖維直徑為121μm。另一方面,實施例6及比較例1之管柱之吸附體之纖維直徑為260μm。任一管柱之吸附體之填充率均為57%,因此於纖維直徑121μm之管柱與纖維直徑260μm之管柱中,每根管柱之吸附體之表面積不同,因此可認為由此導致蛋白質吸附性能產生差異。 Based on the results in Table 3, it can be seen that for a pipe string with the same fiber diameter and filling rate of the adsorbent, the relationship between the air removal rate in the pipe string and the β 2 -MG clearance rate is that the lower the air removal rate in the column, the β 2 -MG The lower the clearance rate, the lower the adsorption performance of the protein. Moreover, in the results of Table 3, the fiber diameter of the adsorbent of the column of Examples 4 and 5 was 121 μm. On the other hand, the fiber diameter of the adsorbent of the column of Example 6 and Comparative Example 1 was 260 μm. The filling rate of the adsorbent of any column is 57%. Therefore, the surface area of the adsorbent of each column is different in a column with a fiber diameter of 121 μm and a column with a fiber diameter of 260 μm, so it can be considered that this results in protein Difference in adsorption performance.

Claims (5)

一種血液淨化管柱,其特徵在於:具有吸附體、與兩端為開放端之套管,於上述套管之內部收容有吸附體,上述套管兩端之一端為血液流入側端部,另一端為血液流出端部,於上述套管之血液流入側端部及/或血液流出側端部配置有過濾片,且滿足以下之必要條件:(1)過濾片之開口率為5%以上且80%以下(2)過濾片之網眼之當量直徑為1μm以上且5000μm以下(3)過濾片之網眼之當量直徑相對於上述吸附體之空隙之平均圓當量直徑的比率為45%以上(4)吸附體之形態為實心纖維狀,該實心纖維狀係沿管柱長度方向平行配置(5)過濾片中,當將於與管柱內之長度方向垂直之方向呈開口之部分的表面積設為B1、將於與管柱內之長度方向平行之方向呈開口之部分的總表面積設為B2之情形時,滿足以下之關係:B1/B2≧1(6)過濾片之形狀為網狀。A blood purification tube string is characterized in that it has an adsorbent body and a sleeve with open ends at both ends. The adsorbent body is accommodated inside the sleeve, and one end of the two ends of the sleeve is a blood inflow side end. One end is a blood outflow end, and a filter is arranged at the blood inflow side end and / or the blood outflow side end of the above-mentioned cannula, and the following necessary conditions are satisfied: (1) the opening rate of the filter is 5% or more and 80% or less (2) The equivalent diameter of the mesh of the filter is 1 μm or more and 5000 μm or less (3) The ratio of the equivalent diameter of the mesh of the filter to the average circular equivalent diameter of the voids of the adsorbent is 45% or more ( 4) The shape of the adsorbent is solid fibrous. The solid fibrous is arranged in parallel along the length of the column. (5) In the filter, the surface area of the portion that will open in a direction perpendicular to the length in the column is set. For B1, when the total surface area of the portion that is open in a direction parallel to the longitudinal direction in the column is set to B2, the following relationship is satisfied: B1 / B2 ≧ 1 (6) The shape of the filter is mesh. 如申請專利範圍第1項之血液淨化管柱,其中,上述過濾片包含選自聚烯烴系樹脂、聚醯胺系樹脂、氟系樹脂中之至少1種素材。For example, the blood purification tube string of the first patent application range, wherein the filter sheet includes at least one material selected from the group consisting of polyolefin resin, polyamide resin, and fluorine resin. 如申請專利範圍第1或2項之血液淨化管柱,其中,上述吸附體於上述管柱內收容空間中之填充率為30%以上且未滿70%。For example, the blood purification tube string of the first or second patent application range, wherein the filling rate of the adsorbent in the storage space in the tube string is 30% or more and less than 70%. 如申請專利範圍第1項之血液淨化管柱,其中,上述實心纖維之纖維直徑或外徑為10μm以上且1000μm以下。For example, the blood purification tube string of the first patent application range, wherein the fiber diameter or outer diameter of the solid fiber is 10 μm or more and 1000 μm or less. 如申請專利範圍第1或2項之血液淨化管柱,其可用於與人工腎臟串列連接之用途。For example, the blood purification tube string of the scope of patent application No. 1 or 2 can be used for serial connection with artificial kidneys.
TW103104538A 2013-02-12 2014-02-12 Blood purification column TWI652078B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-024040 2013-02-12
JP2013024040 2013-02-12

Publications (2)

Publication Number Publication Date
TW201446289A TW201446289A (en) 2014-12-16
TWI652078B true TWI652078B (en) 2019-03-01

Family

ID=51354017

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103104538A TWI652078B (en) 2013-02-12 2014-02-12 Blood purification column

Country Status (9)

Country Link
US (1) US10213543B2 (en)
EP (1) EP2957306B1 (en)
JP (2) JP6414049B2 (en)
KR (1) KR102300302B1 (en)
CN (1) CN104902941B (en)
CA (1) CA2897711C (en)
ES (1) ES2714832T3 (en)
TW (1) TWI652078B (en)
WO (1) WO2014126014A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104147653B (en) * 2014-08-27 2016-08-17 珠海健帆生物科技股份有限公司 There is blood perfusion device of anticoagulant slow-release function and preparation method thereof
KR102435360B1 (en) * 2014-10-28 2022-08-23 도레이 카부시키가이샤 Porous fibers, adsorbent material, and purification column
JP6728743B2 (en) * 2015-03-31 2020-07-22 東レ株式会社 Purification column
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
EP3422943A4 (en) * 2016-03-02 2019-10-16 ExThera Medical Corporation Method for treating drug intoxication
CN105771014A (en) * 2016-03-29 2016-07-20 艾沃生物科技(苏州)有限公司 Plasma filter capable of adsorbing OFR (oxygen free radical)
JP6834677B2 (en) * 2016-03-30 2021-02-24 東レ株式会社 Adsorption column
CA3019094C (en) * 2016-03-30 2024-02-06 Toray Industries, Inc. Fiber material and purification column
RU2715533C1 (en) * 2016-04-27 2020-02-28 Торэй Индастриз, Инк. Porous fibre, adsorbing material and cleaning column
JP7022373B2 (en) * 2017-01-30 2022-02-18 東レ株式会社 Purification column
CA3107352A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
JP2022510573A (en) 2018-07-23 2022-01-27 エンクリアー セラピーズ, インク. How to treat neuropathy
CN109758631B (en) * 2019-01-28 2020-10-27 苏州卓壹医疗器械有限公司 Adsorption type hemodialyzer
CN109758633A (en) * 2019-01-28 2019-05-17 江苏关怀医疗科技有限公司 A kind of filiform adsorbent perfusion device
JP2022526671A (en) * 2019-04-11 2022-05-25 エンクリアー セラピーズ, インク. Methods for improving cerebrospinal fluid and devices and systems for that purpose
CA3148773A1 (en) * 2019-08-01 2021-02-04 Sigyn Therapeutics, Inc. Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood
CN113262762B (en) * 2021-05-06 2023-04-21 西安蓝深新材料科技股份有限公司 Adsorption material for blood perfusion and preparation method thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5995051A (en) 1983-10-31 1984-05-31 テルモ株式会社 Apparatus for fractionating and purifying blood
US4762787A (en) * 1986-11-21 1988-08-09 Imre Corporation Anti-human IGM immunoadsorbent and process for producing said immunoadsorbent
JPH0653168B2 (en) 1986-12-23 1994-07-20 鐘淵化学工業株式会社 Adsorption type blood purifier manufacturing method and manufacturing apparatus used therefor
US5149425A (en) * 1988-11-09 1992-09-22 Chembiomed, Ltd. Affinity supports for hemoperfusion
US5139668A (en) * 1989-12-27 1992-08-18 Alberta Research Corporation Hollow fiber bundle element
US5580349A (en) * 1993-09-17 1996-12-03 Avecor Cardiovascular, Inc. Blood reservoir
DE69514608T2 (en) * 1994-10-13 2000-09-21 Toyota Motor Co Ltd Particle filter
US6241886B1 (en) * 1995-06-09 2001-06-05 Toyo Boseki Kabushiki Kaisha Plasma separation filter
DE69734749T2 (en) * 1996-01-31 2006-09-07 Kaneka Corp. DEVICE WITH ADSORBENS FOR THE ADSORPTIVE REMOVAL OF ILLNESSIFICATED FACTORS IN BODY FLUIDS
JPH09266948A (en) * 1996-01-31 1997-10-14 Kanegafuchi Chem Ind Co Ltd Blood purifying device and blood purifying equipment
US5980612A (en) * 1998-01-21 1999-11-09 Compliance Environmental Management, Inc. Adsorbent activated carbon fiber sheet filter and method of regeneration
US6302860B1 (en) * 1999-02-17 2001-10-16 Medtronic, Inc. Venous filter for assisted venous return
US6416293B1 (en) * 1999-07-20 2002-07-09 Deka Products Limited Partnership Pumping cartridge including a bypass valve and method for directing flow in a pumping cartridge
EP1356832B1 (en) * 2001-01-30 2012-07-11 Kaneka Corporation Body fluid processor enabling direct hemoperfusion
JP2003225304A (en) 2002-02-05 2003-08-12 Toray Ind Inc Body fluid cleaning column
ATE414724T1 (en) * 2002-06-17 2008-12-15 Asahi Kasei Kuraray Medical Co BIOCOMPATIBLE POLYMER AND FILTER FOR SELECTIVE ELIMINATION OF LEUKOCYTES USING THE POLYMER
ES2737433T3 (en) * 2002-08-21 2020-01-14 Toray Industries Modified membrane substrate with reduced platelet adsorption
CA2519812C (en) * 2003-03-24 2009-01-13 Jms Co., Ltd. Blood filter device and method of producing the same
US7896264B2 (en) * 2003-06-30 2011-03-01 Boehringer Ingelheim International Gmbh Microstructured high pressure nozzle with built-in filter function
JP2007298502A (en) * 2006-04-04 2007-11-15 Fujifilm Corp Filter for separating blood cells
CN101088598A (en) * 2006-06-12 2007-12-19 天津协成昌国际贸易有限公司 Prepn and product of adsorbing material
CN103071192B (en) * 2006-09-15 2016-04-27 东丽株式会社 Base material and manufacture method thereof
JP5136418B2 (en) * 2006-09-29 2013-02-06 東レ株式会社 Cell adsorption column
JP5271781B2 (en) 2008-11-25 2013-08-21 日機装株式会社 Blood cell removal module and method for manufacturing blood cell removal module
KR101179638B1 (en) * 2008-04-18 2012-09-04 니기소 가부시키가이샤 Adsorbent for the removal of blood cells
JP4473324B2 (en) 2008-04-18 2010-06-02 日機装株式会社 Adsorbent for removing blood cells
CN201211354Y (en) * 2008-05-21 2009-03-25 珠海丽珠医用生物材料有限公司 Disposable blood perfusion device
WO2011040310A1 (en) * 2009-09-30 2011-04-07 テルモ株式会社 Drug-adsorbing material and medical device comprising same
CN201664579U (en) * 2010-03-23 2010-12-08 东莞科威医疗器械有限公司 Plugging structure of hollow fiber blood ultrafilter
JP2011224142A (en) * 2010-04-20 2011-11-10 Nikkiso Co Ltd Bead-like adsorbent, and blood purifier using the same
US9867917B2 (en) * 2010-12-28 2018-01-16 Toray Industries, Inc. Medical material and hollow fiber membrane module
US20120219633A1 (en) * 2011-02-28 2012-08-30 Pall Corporation Removal of immunoglobulins and leukocytes from biological fluids
JPWO2013129384A1 (en) 2012-03-02 2015-07-30 東レ株式会社 Adsorption column

Also Published As

Publication number Publication date
EP2957306A1 (en) 2015-12-23
JP6414049B2 (en) 2018-10-31
EP2957306A4 (en) 2016-10-19
JPWO2014126014A1 (en) 2017-02-02
JP6638787B2 (en) 2020-01-29
JP2019010549A (en) 2019-01-24
TW201446289A (en) 2014-12-16
CA2897711C (en) 2020-04-28
CN104902941A (en) 2015-09-09
CA2897711A1 (en) 2014-08-21
EP2957306B1 (en) 2019-01-02
CN104902941B (en) 2017-05-03
ES2714832T3 (en) 2019-05-30
KR102300302B1 (en) 2021-09-09
US10213543B2 (en) 2019-02-26
WO2014126014A1 (en) 2014-08-21
KR20150118085A (en) 2015-10-21
US20150374898A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
TWI652078B (en) Blood purification column
US20230093577A1 (en) Blood processing cartridges and systems, and methods for extracorporeal blood therapies
RU2661275C2 (en) Dialysis apparatus with dialyzer
CA3001444A1 (en) Phosphorus adsorbent, porous fiber and phosphorus adsorption column
EP1572330A1 (en) Perm selective asymmetric hollow fibre membrane for the separation of toxic mediators from blood
JP6565187B2 (en) Porous membrane, blood purification module incorporating porous membrane, and method for producing porous membrane
JP5873170B2 (en) Method and apparatus for producing high concentration protein solution
JP2017104853A (en) Phosphorus adsorbent, porous fiber, and phosphorus adsorption column
Roy et al. State-of-the-art materials and spinning technology for hemodialyzer membranes
JP6874336B2 (en) Porous fiber and phosphorus adsorption column
Sakai Dialysis membranes for blood purification
Bowry et al. The scientific principles and technological determinants of haemodialysis membranes
Catapano et al. Blood flow outside regularly spaced hollow fibers: the future concept of membrane devices?
JP6834677B2 (en) Adsorption column
JP6924357B2 (en) Adsorbed fiber bundle and body fluid purification column
JP4144843B2 (en) Hollow fiber membrane dialysis filter
JP7224104B2 (en) Dialysis device with improved internal filtration and method of manufacture
JP5062773B2 (en) Blood purifier
Neri et al. Membranes and filters for use in acute renal failure
WO2018126333A1 (en) Integrated blood purifier
JP2019193709A (en) Amyloid-β removal system
Clarka et al. Membranes for Dialysis